Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS	12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	13	APR 26	PROMT: New display field available
NEWS	14	APR 26	FIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	15	APR 26	LITALERT now available on STN
NEWS	16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:03:54 ON 28 APR 2004

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:04:22 ON 28 APR 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6
DICTIONARY FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10715283.5

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Cy,Hy

G2 O,CH2,NH,NH2

G3 H,OH,COOH,CN,NO2,Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

Patel <4/28/2004>

```
=> s l1 sss full
FULL SEARCH INITIATED 13:04:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 111326 TO ITERATE

100.0% PROCESSED  111326 ITERATIONS                          434 ANSWERS
SEARCH TIME: 00.00.02

L2          434 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                             155.42     155.63

FILE 'CAPLUS' ENTERED AT 13:04:56 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 28 Apr 2004  VOL 140 ISS 18
FILE LAST UPDATED: 27 Apr 2004  (20040427/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l2
L3          307 L2

=> s l3 and phenyl
L4           94 L3 AND PHENYL

=> s l3 and thiophene
L5           11 L3 AND THIOPHENE

=> s l3 and diseases
L6            5 L3 AND DISEASES

=> d l6 fbib hitstr abs total

L6   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2003:319888  CAPLUS
DN   138:338170
TI   Preparation of piperazinecyclohexanecarboxylic acid amides as adenosine
```

uptake inhibitors for the treatment of cardiovascular **diseases**
IN Bischoff, Erwin; Krahn, Thomas; Paulsen, Holger; Schuhmacher, Joachim; Steinhagen, Henning; Thielemann, Wolfgang
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003033484	A1	20030424	WO 2002-EP10978	20021001

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 2001-10150310A 20011011

DE 10150310 A1 20030424 DE 2001-10150310 20011011

OS MARPAT 138:338170
IT **515148-15-9P 515148-22-8P 515148-26-2P**
515148-30-8P 515148-33-1P 515148-34-2P
515148-35-3P 515148-40-0P 515148-45-5P
515148-53-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of piperazinecyclohexanecarboxylic acid amides as adenosine uptake inhibitors for the treatment of cardiovascular **diseases**)
RN 515148-15-9 CAPLUS
CN Cyclohexanecarboxylic acid, 2-(4-benzoyl-1-piperazinyl)-, (1R,2R)-rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 515148-14-8
CMF C18 H24 N2 O3

Relative stereochemistry.



Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 5	FEB 05	German (DE) application and patent publication number format changes
NEWS 6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 8	MAR 03	FRANCEPAT now available on STN
NEWS 9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 10	MAR 29	WPIFV now available on STN
NEWS 11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS 12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 13	APR 26	PROMT: New display field available
NEWS 14	APR 26	FIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS 15	APR 26	LITALERT now available on STN
NEWS 16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:58:49 ON 28 APR 2004

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:58:59 ON 28 APR 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6
DICTIONARY FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10715283.4

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Cy,Hy
G2 O,CH2,NH,NH2
G3 H,OH,COOH,CN,NO2,Cb,Cy,Hy,Ak

Patel <4/28/2004>

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 12:59:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     22 TO ITERATE

100.0% PROCESSED      22 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.03

L2             0 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   155.42     155.63

FILE 'MARPAT' ENTERED AT 12:59:31 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 17)(20040423/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US    6709645 23 MAR 2004
DE   10335606 11 MAR 2004
EP    1403278 31 MAR 2004
JP 2004099560 02 APR 2004
WO 2004024934 25 MAR 2004

Structure search limits have been raised.  See HELP SLIMIT for the new,
higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 12:59:37 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -   2534 TO ITERATE

100.0% PROCESSED    2534 ITERATIONS                              1 ANSWERS
SEARCH TIME: 00.00.10

L3             1 SEA SSS FUL L1

=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   109.42     265.05

FILE 'CAOLD' ENTERED AT 12:59:52 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)
```

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l1 sss full
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 12:59:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 22 TO ITERATE

100.0% PROCESSED 22 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L4 0 SEA SSS FUL L1

L5 0 L4

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	421.31

FILE 'CAPLUS' ENTERED AT 13:00:02 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Apr 2004 VOL 140 ISS 18
FILE LAST UPDATED: 27 Apr 2004 (20040427/ED)

This file contains CAS Registry Numbers for easy and accurate

substance identification.

```
=> d his

     (FILE 'HOME' ENTERED AT 12:58:49 ON 28 APR 2004)

     FILE 'REGISTRY' ENTERED AT 12:58:59 ON 28 APR 2004
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS FULL

     FILE 'MARPAT' ENTERED AT 12:59:31 ON 28 APR 2004
L3           1 S L1 SSS FULL

     FILE 'CAOLD' ENTERED AT 12:59:52 ON 28 APR 2004
               S L1

     FILE 'REGISTRY' ENTERED AT 12:59:57 ON 28 APR 2004
L4           0 S L1 SSS FULL

     FILE 'CAOLD' ENTERED AT 12:59:58 ON 28 APR 2004
L5           0 S L4 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:00:02 ON 28 APR 2004

=> s l3
L6           1 L3

=> d l6 fbib hitstr abs total

L6   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2002:185069  CAPLUS
DN   136:232117
TI   Substituted phenylcyclohexanecarboxylic acid amides and their use in
     treating cardiovascular disease
IN   Bischoff, Erwin; Krahn, Thomas; Mueller, Stephan-Nicholas; Paulsen,
     Holger; Schuhmacher, Joachim; Steinhagen, Henning; Thielemann, Wolfgang
PA   Bayer Aktiengesellschaft, Germany
SO   PCT Int. Appl., 143 pp.
     CODEN: PIXXD2
DT   Patent
LA   German
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2002020472     A1    20020314       WO 2001-EP9938   20010829
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                            DE 2000-10044792A 20000911
     DE 10044792       A1    20020404       DE 2000-10044792 20000911
     AU 2002012176     A5    20020322       AU 2002-12176    20010829
```

				DE 2000-10044792A 20000911
				WO 2001-EP9938 W 20010829
EP 1318977		A1	20030618	EP 2001-980296 20010829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU; NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				DE 2000-10044792A 20000911
				WO 2001-EP9938 W 20010829
BR 2001013814		A	20030708	BR 2001-13814 20010829
				DE 2000-10044792A 20000911
				WO 2001-EP9938 W 20010829
JP 2004508350		T2	20040318	JP 2002-525095 20010829
				DE 2000-10044792A 20000911
				WO 2001-EP9938 W 20010829
US 2003008881		A1	20030109	US 2001-943325 20010830
US 6649616		B2	20031118	
				DE 2000-10044792A 20000911

OS MARPAT 136:232117

GI



I II

AB Title compds. I [D = (un)substituted C6H4, thiophene-2,5-diyl; A = O, (un)substituted NH, CH2; R1 = H, alkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, (un)substituted aryl, heteroaryl, NH2, OH; R2 = (un)substituted alkyl, aryl, heteroaryl; R3 = (un)substituted CONH2] were prepared for use as adenosine uptake inhibitors in the treatment of cardiovascular disease. Thus, tert.-Bu (1R,2R)-2-(4-bromomethylphenyl)cyclohexanecarboxylate was treated with 4-(N-phenylcarbamoyl)morpholine, followed by ester hydrolysis and amidation with L-phenylglycinamide-HCl to give the amide II. II had an IC50 of 30 nM for inhibition of adenosine uptake in rabbit erythrocytes.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.98	424.29
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.69	-0.69

STN INTERNATIONAL LOGOFF AT 13:00:38 ON 28 APR 2004

Patel <4/28/2004>

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS 4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS 5	FEB 05	German (DE) application and patent publication number format changes
NEWS 6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS 7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS 8	MAR 03	FRANCEPAT now available on STN
NEWS 9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS 10	MAR 29	WPIFV now available on STN
NEWS 11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS 12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 13	APR 26	PROMT: New display field available
NEWS 14	APR 26	FIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS 15	APR 26	LITALERT now available on STN
NEWS 16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:39:36 ON 28 APR 2004

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:39:57 ON 28 APR 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6
DICTIONARY FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10715283.1

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Cy,Hy
G2 O,CH2,NH,NH2
G3 H,OH,COOH,CN,NO2,Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

Patel <4/28/2004>

```
=> s l1 sss full
FULL SEARCH INITIATED 12:40:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  84380 TO ITERATE

100.0% PROCESSED   84380 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.08

L2            0 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   155.42     155.63

FILE 'MARPAT' ENTERED AT 12:40:38 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 17)(20040423/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US    6709645 23 MAR 2004
DE   10335606 11 MAR 2004
EP    1403278 31 MAR 2004
JP 2004099560 02 APR 2004
WO 2004024934 25 MAR 2004

Structure search limits have been raised.  See HELP SLIMIT for the new,
higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 12:40:43 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -  16378 TO ITERATE

 54.8% PROCESSED    8983 ITERATIONS  (     1 INCOMPLETE)        1 ANSWERS

 80.0% PROCESSED   13106 ITERATIONS  (     1 INCOMPLETE)        1 ANSWERS

 95.5% PROCESSED   15634 ITERATIONS  (     1 INCOMPLETE)        1 ANSWERS

 99.3% PROCESSED   16270 ITERATIONS  (     1 INCOMPLETE)        1 ANSWERS

100.0% PROCESSED   16378 ITERATIONS  (     1 INCOMPLETE)        1 ANSWERS
SEARCH TIME: 00.01.18

L3            1 SEA SSS FUL L1

=> file caold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   110.26     265.89

FILE 'CAOLD' ENTERED AT 12:42:09 ON 28 APR 2004
```

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGistRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l1 sss full
REGistRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 12:42:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 84380 TO ITERATE

100.0% PROCESSED 84380 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.07

L4 0 SEA SSS FUL L1

L5 0 L4

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	422.15

FILE 'CAPLUS' ENTERED AT 12:42:31 ON 28 APR 2004

FILE COVERS 1907 - 28 Apr 2004 VOL 140 ISS 18
FILE LAST UPDATED: 27 Apr 2004 (20040427/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 12:39:36 ON 28 APR 2004)

FILE 'REGISTRY' ENTERED AT 12:39:57 ON 28 APR 2004
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 12:40:38 ON 28 APR 2004
L3 1 S L1 SSS FULL

FILE 'CAOLD' ENTERED AT 12:42:09 ON 28 APR 2004
S L1

FILE 'REGISTRY' ENTERED AT 12:42:18 ON 28 APR 2004
L4 0 S L1 SSS FULL

FILE 'CAOLD' ENTERED AT 12:42:25 ON 28 APR 2004
L5 0 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 12:42:31 ON 28 APR 2004

=> s l3
L6 1 L3

=> d l6 fbib hitstr abs total

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:245602 CAPLUS
DN **120:245602**
TI Preparation of 17-ethers and thioethers of 4-aza-steroids as steroid reductase inhibitors
IN Witzel, Bruce E.; Tolman, Richard L.; Rasmusson, Gary H.; Bakshi, Raman K.; Yang, Shu Shu
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9323040	A1	19931125	WO 1993-US4746	19930519
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
			US 1992-886031	A219920520
AU 9342521	A1	19931213	AU 1993-42521	19930519

AU 668180	B2	19960426		
			US 1992-886031 A	19920520
			WO 1993-US4746 A	19930519
EP 641204	A1	19950308	EP 1993-911358	19930519
EP 641204	B1	20000816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
			US 1992-886031 A	19920520
			WO 1993-US4746 W	19930519
JP 07508038	T2	19950907	JP 1993-503831	19930519
			US 1992-886031 A	19920520
			WO 1993-US4746 W	19930519
AT 195530	E	20000915	AT 1993-911358	19930519
			US 1992-886031 A	19920520
			WO 1993-US4746 W	19930519
ES 2148229	T3	20001016	ES 1993-911358	19930519
			US 1992-886031 A	19920520
US 5536727	A	19960716	US 1994-338572	19941117
			US 1992-886031 B2	19920520
			WO 1993-US4746 W	19930519

PATENT FAMILY INFORMATION:

FAN 1996:469929

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5536727	A	19960716	US 1994-338572	19941117
			US 1992-886031 B2	19920520
			WO 1993-US4746 W	19930519
WO 9323040	A1	19931125	WO 1993-US4746	19930519
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
			US 1992-886031 A2	19920520

OS MARPAT 120:245602

GI



I

AB Title compds. [I; a, b both = single bonds, and R2 = H; or a = double bond, b = single bond, and R2 = H; or a = single bond, b = double bond, and R2 = null; R1 = H, aryl, (aryl)alkyl; R3 = H, Me, Et, OH, NH2, SMe; R4 = (substituted) alkyl, aryl, heterocyclyl; Z = XR4, (CHR1)nXR4; X = O, S, SO, SO2], were prepared as inhibitors of steroid 5α-reductase enzymes 1 and 2 (no data). The compds. are useful for the treatment of hyperandrogenic disease conditions and diseases of the skin and scalp. Thus, 17-hydroxymethyl-4-methyl-5α-4-azaandrostan-3-one and diphenyldiazomethane in CH2Cl2 were treated dropwise with BF3.Et2O to give 17-diphenylmethoxymethyl-4-methyl-5α-4-azaandrostan-3-one.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.28	431.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.69	-0.69

STN INTERNATIONAL LOGOFF AT 12:43:03 ON 28 APR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS	12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	13	APR 26	PROMT: New display field available
NEWS	14	APR 26	FIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	15	APR 26	LITALERT now available on STN
NEWS	16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:44:17 ON 28 APR 2004

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:44:40 ON 28 APR 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6
DICTIONARY FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10715283.2

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Cy,Hy
G2 O,CH2,NH,NH2
G3 H,OH,COOH,CN,NO2,Cb,Cy,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss full
FULL SEARCH INITIATED 12:45:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  86549 TO ITERATE

100.0% PROCESSED   86549 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.06

L2            4 SEA SSS FUL L1

=> file marpat
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   156.26     156.47

FILE 'MARPAT' ENTERED AT 12:46:10 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 140 ISS 17)(20040423/ED)

MOST RECENT CITATIONS FOR PATENTS FROM FIVE MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US    6709645 23 MAR 2004
DE   10335606 11 MAR 2004
EP    1403278 31 MAR 2004
JP 2004099560 02 APR 2004
WO 2004024934 25 MAR 2004

Structure search limits have been raised.  See HELP SLIMIT for the new,
higher limits.

=> s l1 sss full
FULL SEARCH INITIATED 12:46:16 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -  16378 TO ITERATE

 52.6% PROCESSED    8616 ITERATIONS  (     1 INCOMPLETE)        1 ANSWERS

 79.3% PROCESSED   12981 ITERATIONS  (     1 INCOMPLETE)        3 ANSWERS

 89.7% PROCESSED   14691 ITERATIONS  (     1 INCOMPLETE)        3 ANSWERS

 99.1% PROCESSED   16226 ITERATIONS  (     1 INCOMPLETE)        4 ANSWERS

100.0% PROCESSED   16378 ITERATIONS  (     1 INCOMPLETE)        4 ANSWERS
SEARCH TIME: 00.01.17

L3            4 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   110.26     266.73

FILE 'CAPLUS' ENTERED AT 12:48:07 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
```

FILE COVERS 1907 - 28 Apr 2004 VOL 140 ISS 18
FILE LAST UPDATED: 27 Apr 2004 (20040427/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 12:44:17 ON 28 APR 2004)

FILE 'REGISTRY' ENTERED AT 12:44:40 ON 28 APR 2004
L1 STRUCTURE UPLOADED
L2 4 S L1 SSS FULL

FILE 'MARPAT' ENTERED AT 12:46:10 ON 28 APR 2004
L3 4 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 12:48:07 ON 28 APR 2004

=> s l2
L4 2 L2

=> s l3
L5 4 L3

=> d l4 fbib hitstr abs total

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:319888 CAPLUS
DN 138:338170
TI Preparation of piperazinecyclohexanecarboxylic acid amides as adenosine uptake inhibitors for the treatment of cardiovascular diseases
IN Bischoff, Erwin; Krahn, Thomas; Paulsen, Holger; Schuhmacher, Joachim; Steinhagen, Henning; Thielemann, Wolfgang
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003033484	A1	20030424	WO 2002-EP10978	20021001

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 2001-10150310A 20011011

DE 10150310 A1 20030424 DE 2001-10150310 20011011

OS MARPAT 138:338170

IT **515146-49-3P 515146-80-2P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of piperazinecyclohexanecarboxylic acid amides as adenosine uptake inhibitors for the treatment of cardiovascular diseases)

RN 515146-49-3 CAPLUS

CN Cyclohexanecarboxamide, N-[1-(aminocarbonyl)-3-(methylsulfonyl)propyl]-2-[4-(phenylmethyl)-1-piperazinyl]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 515146-80-2 CAPLUS

CN Cyclohexanecarboxamide, N-[(1S)-1-(aminocarbonyl)-3-(methylsulfonyl)propyl]-2-[4-(4-methoxybenzoyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



I



II



III

AB Title compds. I [R1 = COR4, (CH2)aR4, SO2R4, etc.; R4 = (un)substituted alkyl; cycloalkyl, alkylaryl, etc.; R2 = (un)substituted alkyl, e.g., OH, oxo; R3 = CH2OH, CONR8R9; R8, R9 = H, alkyl; a = 0-3]and their pharmaceutically acceptable salts were prepared For example, coupling of an enantiomeric mixture of trans-aminocyclohexane carboxylic acids·TFA II, e.g., prepared from 1-cyclohexene-1-carboxylic acid in 4-steps, and (αS)-aminobenzeneacetamide·HCL, followed by HPLC separation of the diastereomeric mixture, afforded claimed piperazine III in 35% yield. In rabbit erythrocyte adenosine uptake inhibition assays, 10-examples of compds. I exhibited IC50 values ranging from 15-80 nM, e.g., the IC50 value of piperazine III was 30 nM. Compds. I are claimed useful for the prophylaxis and/or the treatment of cardiovascular diseases.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:185069 CAPLUS
DN 136:232117
TI Substituted phenylcyclohexanecarboxylic acid amides and their use in treating cardiovascular disease
IN Bischoff, Erwin; Krahn, Thomas; Mueller, Stephan-Nicholas; Paulsen, Holger; Schuhmacher, Joachim; Steinhagen, Henning; Thielemann, Wolfgang
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020472	A1	20020314	WO 2001-EP9938	20010829
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DE 2000-10044792A	20000911
	DE 10044792	A1	20020404	DE 2000-10044792	20000911
	AU 2002012176	A5	20020322	AU 2002-12176	20010829
				DE 2000-10044792A	20000911
				WO 2001-EP9938 W	20010829
	EP 1318977	A1	20030618	EP 2001-980296	20010829
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				DE 2000-10044792A	20000911
				WO 2001-EP9938 W	20010829
	BR 2001013814	A	20030708	BR 2001-13814	20010829
				DE 2000-10044792A	20000911
				WO 2001-EP9938 W	20010829
	JP 2004508350	T2	20040318	JP 2002-525095	20010829
				DE 2000-10044792A	20000911
				WO 2001-EP9938 W	20010829
	US 2003008881	A1	20030109	US 2001-943325	20010830
	US 6649616	B2	20031118		
				DE 2000-10044792A	20000911

OS MARPAT 136:232117

IT **403600-22-6P 403601-19-4P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted phenylcyclohexanecarboxylic acid amides and their use in treating cardiovascular disease)

RN 403600-22-6 CAPLUS

CN Cyclohexanecarboxamide, N-[(1S)-1-(aminocarbonyl)-3-(methylsulfonyl)propyl]-2-[4-[[[(dimethylamino)carbonyl]phenylamino]methyl]phenyl]-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-19-4 CAPLUS
CN Carbamic acid, ethyl-, [4-[(1R,2R)-2-[[[(1S)-1-(aminocarbonyl)-3-(methylsulfonyl)propyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



I



II

AB Title compds. I [D = (un)substituted C6H4, thiophene-2,5-diyl; A = O, (un)substituted NH, CH2; R1 = H, alkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, (un)substituted aryl, heteroaryl, NH2, OH; R2 = (un)substituted alkyl, aryl, heteroaryl; R3 = (un)substituted CONH2] were prepared for use as adenosine uptake inhibitors in the treatment of cardiovascular disease. Thus, tert.-Bu (1R,2R)-2-(4-bromomethylphenyl)cyclohexanecarboxylate was treated with 4-(N-phenylcarbamoyl)morpholine, followed by ester hydrolysis and amidation with L-phenylglycinamide-HCl to give the amide II. II had an IC50 of 30 nM for inhibition of adenosine uptake in rabbit erythrocytes.
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

=> d l5 fbib hitstr abs total

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:511283 CAPLUS

DN **139:85038**
TI Preparation of TNF-α inhibiting hydroxyamic or carboxylic acid functionalized cycloalkanes for the treatment of inflammatory disorders
IN Zhu, Zhaoning; Mazzola, Robert, Jr.; Guo, Zhuyan; Lavey, Brian J.; Sinning, Lisa; Kozlowski, Joseph; McKittrick, Brian; Shih, Neng-Yang
PA Schering Corporation, USA
SO PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003053915	A2	20030703	WO 2002-US40453	20021219
	WO 2003053915	A3	20030918		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2001-342332PP	20011220
	US 2004038941	A1	20040226	US 2002-323511	20021219
				US 2001-342332PP	20011220

OS MARPAT 139:85038
GI



I



II



III

AB This invention relates to compds. of formula I [M = -(C(R30)(R40))m-, wherein m = 1-6; T = substituted alkyl, (un)substituted-cycloalkyl, -heterocycloalkyl, -aryl, etc.; V = (un)substituted alkyl, cycloalkyl, heteroaryl, etc.; R1 = (un)substituted alkyl, alkyne, alkene, cycloalkyl,

aryl, etc.; R2 = H, halo, (un)substituted alkyl, cycloalkyl, etc.; U = bond, alkyl, heteroalkyl, heteroatoms; X = (un)substituted alkylene, cycloalkylene, arylene, etc.; W = carboxy, substituted iminomethylene, SO2, SO, etc., wherein n = 0-2; R30 and R40 independently = H or halo, CN, NO2, (un)substituted alkyl, etc.; or R30 and R40 may be taken together with the atom to which they are attached to form C=O, with provisions] or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, TNF-alpha or combinations thereof. Thus, II was prepared from Me methoxyphenylethanoate with the cyclopropane ring diastereoselectively formed by cyclization of intermediate III with S-carbo-tert-butoxymethyltetrahydrothiophene bromide with subsequent hydrogenation and resolution of enantiomers. Numerous compds. of the invention possessed Ki values of less than 20 nM in a TNF-α convertases (TACE) inhibitory activity assay. As TNF-α inhibitors, I will be useful in treatment of inflammatory disorders.

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:319888 CAPLUS
DN **138:338170**
TI Preparation of piperazinecyclohexanecarboxylic acid amides as adenosine uptake inhibitors for the treatment of cardiovascular diseases
IN Bischoff, Erwin; Krahn, Thomas; Paulsen, Holger; Schuhmacher, Joachim; Steinhagen, Henning; Thielemann, Wolfgang
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003033484	A1	20030424	WO 2002-EP10978	20021001
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DE 2001-10150310A	20011011
	DE 10150310	A1	20030424	DE 2001-10150310	20011011

OS MARPAT 138:338170
GI



I



II



III

AB Title compds. I [R1 = COR4, (CH2)aR4, SO2R4, etc.; R4 = (un)substituted alkyl, cycloalkyl, alkylaryl, etc.; R2 = (un)substituted alkyl, e.g., OH, oxo; R3 = CH2OH, CONR8R9; R8, R9 = H, alkyl; a = 0-3]and their pharmaceutically acceptable salts were prepared For example, coupling of an enantiomeric mixture of trans-aminocyclohexane carboxylic acids·TFA II, e.g., prepared from 1-cyclohexene-1-carboxylic acid in 4-steps, and (αS)-aminobenzeneacetamide·HCL, followed by HPLC separation of the diastereomeric mixture, afforded claimed piperazine III in 35% yield. In rabbit erythrocyte adenosine uptake inhibition assays, 10-examples of compds. I exhibited IC50 values ranging from 15-80 nM, e.g., the IC50 value of piperazine III was 30 nM. Compds. I are claimed useful for the prophylaxis and/or the treatment of cardiovascular diseases.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:185069 CAPLUS
DN **136:232117**
TI Substituted phenylcyclohexanecarboxylic acid amides and their use in treating cardiovascular disease
IN Bischoff, Erwin; Krahn, Thomas; Mueller, Stephan-Nicholas; Paulsen, Holger; Schuhmacher, Joachim; Steinhagen, Henning; Thielemann, Wolfgang
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002020472	A1	20020314	WO 2001-EP9938	20010829

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 2000-10044792A 20000911

DE 10044792	A1	20020404	DE 2000-10044792 20000911
AU 2002012176	A5	20020322	AU 2002-12176 20010829
			DE 2000-10044792A 20000911
			WO 2001-EP9938 W 20010829
EP 1318977	A1	20030618	EP 2001-980296 20010829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
			DE 2000-10044792A 20000911
			WO 2001-EP9938 W 20010829
BR 2001013814	A	20030708	BR 2001-13814 20010829
			DE 2000-10044792A 20000911
			WO 2001-EP9938 W 20010829
JP 2004508350	T2	20040318	JP 2002-525095 20010829
			DE 2000-10044792A 20000911
			WO 2001-EP9938 W 20010829
US 2003008881	A1	20030109	US 2001-943325 20010830
US 6649616	B2	20031118	

DE 2000-10044792A 20000911

OS MARPAT 136:232117

GI



AB Title compds. I [D = (un)substituted C6H4, thiophene-2,5-diyl; A = O, (un)substituted NH, CH2; R1 = H, alkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, (un)substituted aryl, heteroaryl, NH2, OH; R2 = (un)substituted alkyl, aryl, heteroaryl; R3 = (un)substituted CONH2] were prepared for use as adenosine uptake inhibitors in the treatment of cardiovascular disease. Thus, tert.-Bu (1R,2R)-2-(4-bromomethylphenyl)cyclohexanecarboxylate was treated with 4-(N-phenylcarbamoyl)morpholine, followed by ester hydrolysis and amidation with L-phenylglycinamide-HCl to give the amide II. II had an IC50 of 30 nM for inhibition of adenosine uptake in rabbit erythrocytes.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:245602 CAPLUS
DN **120:245602**
TI Preparation of 17-ethers and thioethers of 4-aza-steroids as steroid reductase inhibitors
IN Witzel, Bruce E.; Tolman, Richard L.; Rasmusson, Gary H.; Bakshi, Raman K.; Yang, Shu Shu
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9323040	A1	19931125	WO 1993-US4746	19930519
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1992-886031 A219920520	
	AU 9342521	A1	19931213	AU 1993-42521	19930519
	AU 668180	B2	19960426		
				US 1992-886031 A 19920520	
				WO 1993-US4746 A 19930519	
	EP 641204	A1	19950308	EP 1993-911358	19930519
	EP 641204	B1	20000816		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				US 1992-886031 A 19920520	
				WO 1993-US4746 W 19930519	
	JP 07508038	T2	19950907	JP 1993-503831	19930519
				US 1992-886031 A 19920520	
				WO 1993-US4746 W 19930519	
	AT 195530	E	20000915	AT 1993-911358	19930519
				US 1992-886031 A 19920520	
				WO 1993-US4746 W 19930519	
	ES 2148229	T3	20001016	ES 1993-911358	19930519
				US 1992-886031 A 19920520	
	US 5536727	A	19960716	US 1994-338572	19941117
				US 1992-886031 B219920520	
				WO 1993-US4746 W 19930519	

PATENT FAMILY INFORMATION:
FAN 1996:469929

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5536727	A	19960716	US 1994-338572	19941117
				US 1992-886031 B219920520	
				WO 1993-US4746 W 19930519	
	WO 9323040	A1	19931125	WO 1993-US4746	19930519
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1992-886031 A219920520	

OS MARPAT 120:245602
GI



I

AB Title compds. [I; a, b both = single bonds, and R2 = H; or a = double bond, b = single bond, and R2 = H; or a = single bond, b = double bond, and R2 = null; R1 = H, aryl, (aryl)alkyl; R3 = H, Me, Et, OH, NH2, SMe; R4 = (substituted) alkyl, aryl, heterocyclyl; Z = XR4, (CHR1)nXR4; X = O, S, SO, SO2], were prepared as inhibitors of steroid 5α-reductase enzymes 1 and 2 (no data). The compds. are useful for the treatment of hyperandrogenic disease conditions and diseases of the skin and scalp. Thus, 17-hydroxymethyl-4-methyl-5α-4-azaandrostan-3-one and diphenyldiazomethane in CH2Cl2 were treated dropwise with BF3.Et2O to give 17-diphenylmethoxymethyl-4-methyl-5α-4-azaandrostan-3-one.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	26.42	293.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.16	-4.16

STN INTERNATIONAL LOGOFF AT 12:48:57 ON 28 APR 2004

Welcome to STN International! Enter x:x

LOGINID:ssspta1611sxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	JAN 27	Source of Registration (SR) information in REGISTRY updated and searchable
NEWS	4	JAN 27	A new search aid, the Company Name Thesaurus, available in CA/CAplus
NEWS	5	FEB 05	German (DE) application and patent publication number format changes
NEWS	6	MAR 03	MEDLINE and LMEDLINE reloaded
NEWS	7	MAR 03	MEDLINE file segment of TOXCENTER reloaded
NEWS	8	MAR 03	FRANCEPAT now available on STN
NEWS	9	MAR 29	Pharmaceutical Substances (PS) now available on STN
NEWS	10	MAR 29	WPIFV now available on STN
NEWS	11	MAR 29	No connect hour charges in WPIFV until May 1, 2004
NEWS	12	MAR 29	New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS	13	APR 26	PROMT: New display field available
NEWS	14	APR 26	FIPAT/IFIUDB/IFICDB: New super search and display field available
NEWS	15	APR 26	LITALERT now available on STN
NEWS	16	APR 27	NLDB: New search and display fields available

NEWS EXPRESS	MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 APRIL 2004
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:51:56 ON 28 APR 2004

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:52:16 ON 28 APR 2004

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6
DICTIONARY FILE UPDATES: 26 APR 2004 HIGHEST RN 676992-14-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading c:\program files\stnexp\queries\10715283.3

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Cb,Cy,Hy

G2 O,CH2,NH,NH2

G3 H,OH,COOH,CN,NO2,Cb,Cy,Hy,Ak

Patel <4/28/2004>

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 12:52:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1465 TO ITERATE

 68.3% PROCESSED    1000 ITERATIONS                                 9 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        27004 TO    31596
PROJECTED ANSWERS:              46 TO      480

L2             9 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 12:52:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  28331 TO ITERATE

100.0% PROCESSED   28331 ITERATIONS                               308 ANSWERS
SEARCH TIME: 00.00.01

L3           308 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                              155.42     155.63

FILE 'CAPLUS' ENTERED AT 12:53:05 ON 28 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 28 Apr 2004  VOL 140 ISS 18
FILE LAST UPDATED: 27 Apr 2004  (20040427/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l3
L4             9 L3
```

=> d 14 fbib hitstr abs total

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:319888 CAPLUS
DN 138:338170
TI Preparation of piperazinecyclohexanecarboxylic acid amides as adenosine uptake inhibitors for the treatment of cardiovascular diseases
IN Bischoff, Erwin; Krahn, Thomas; Paulsen, Holger; Schuhmacher, Joachim; Steinhagen, Henning; Thielemann, Wolfgang
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003033484	A1	20030424	WO 2002-EP10978	20021001

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			DE 2001-10150310A	20011011
DE 10150310	A1	20030424	DE 2001-10150310	20011011

OS MARPAT 138:338170
IT **515146-35-7P 515146-36-8P 515146-37-9P**
515146-38-0P 515146-39-1P 515146-40-4P
515146-41-5P 515146-43-7P 515146-45-9P
515146-47-1P 515146-51-7P 515146-53-9P
515146-54-0P 515146-55-1P 515146-56-2P
515146-58-4P 515146-60-8P 515146-62-0P
515146-64-2P 515146-65-3P 515146-66-4P
515146-67-5P 515146-68-6P 515146-69-7P
515146-70-0P 515146-71-1P 515146-72-2P
515146-73-3P 515146-74-4P 515146-76-6P
515146-77-7P 515146-78-8P 515146-79-9P
515146-82-4P 515146-83-5P 515146-84-6P
515146-85-7P 515146-86-8P 515146-87-9P
515146-88-0P 515146-89-1P 515146-90-4P
515146-91-5P 515146-92-6P 515146-93-7P
515146-94-8P 515146-95-9P 515146-96-0P
515146-97-1P 515146-98-2P 515146-99-3P
515147-00-9P 515147-02-1P 515147-03-2P
515147-04-3P 515147-05-4P 515147-06-5P
515147-07-6P 515147-08-7P 515147-09-8P
515147-10-1P 515147-11-2P 515147-12-3P
515147-13-4P 515147-14-5P 515147-15-6P
515147-16-7P 515147-17-8P 515147-18-9P
515147-19-0P 515147-20-3P 515147-21-4P
515147-22-5P 515147-23-6P 515147-24-7P



I



II



III

AB Title compds. I [R1 = COR4, (CH2)aR4, SO2R4, etc.; R4 = (un)substituted alkyl, cycloalkyl, alkylaryl, etc.; R2 = (un)substituted alkyl, e.g., OH, oxo; R3 = CH2OH, CONR8R9; R8, R9 = H, alkyl; a = 0-3]and their pharmaceutically acceptable salts were prepared For example, coupling of an enantiomeric mixture of trans-aminocyclohexane carboxylic acids·TFA II, e.g., prepared from 1-cyclohexene-1-carboxylic acid in 4-steps, and (αS)-aminobenzeneacetamide·HCL, followed by HPLC separation of the diastereomeric mixture, afforded claimed piperazine III in 35% yield. In rabbit erythrocyte adenosine uptake inhibition assays, 10-examples of compds. I exhibited IC50 values ranging from 15-80 nM, e.g., the IC50 value of piperazine III was 30 nM. Compds. I are claimed useful for the prophylaxis and/or the treatment of cardiovascular diseases.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:408632 CAPLUS
DN 137:5933
TI Preparation of substituted 2-phenyl-1-cyclohexanecarboxamides and related compounds their use in the treatment of cardiovascular, urogenital tract or cerebrovascular diseases.
IN Roehrig, Susanne; Stolle, Andreas; Castro-Palomino, Julio; Hanning, Helmut; Handke, Gabriele; Daviu-Folguera, Noemi; Paulsen, Holger; Pernestorfer, Josef; Mueller, Stephan-Nicholas; Steinhagen, Henning; Thielemann, Wolfgang; Bischoff, Erwin; Ebbinghaus-Kintscher, Ulrich; Ellinghaus, Peter; Huetter, Joachim; Krahn, Thomas; Wunder, Frank; Lustig, Klemens; Schuhmacher, Joachim; Suessmeier, Frank
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 227 pp.
CODEN: PIXXD2
DT Patent
LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002042257	A1	20020530	WO 2001-EP13062	20011112
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DE 2000-10058461A	20001124
	DE 10058461	A1	20020919	DE 2000-10058461	20001124
	AU 2002024839	A5	20020603	AU 2002-24839	20011112
				DE 2000-10058461A	20001124
				WO 2001-EP13062W	20011112
	EP 1339670	A1	20030903	EP 2001-994647	20011112
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				DE 2000-10058461A	20001124
				WO 2001-EP13062W	20011112
	BR 2001015611	A	20040106	BR 2001-15611	20011112
				DE 2000-10058461A	20001124
				WO 2001-EP13062W	20011112

OS MARPAT 137:5933

IT **432045-30-2P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 2-phenyl-1-cyclohexanecarboxamide derivs. for treatment of cardiovascular, urogenital tract or cerebrovascular diseases)

RN 432045-30-2 CAPLUS

CN Benzeneacetamide, α-[[[(1S,2S)-2-[4-[[methyl(1-methyl-1-phenylethyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



I



II



III

AB This invention discloses the preparation of title compds. I and their pharmaceutically acceptable salts for the treatment of cardiovascular, urogenital tract or cerebrovascular diseases [wherein: W = O, N(R1); R1 = H, benzyl, alkenyl, alkyl or (benzo)cycloalkyl optionally substituted by OH, amino, alkoxy, Ph, 5- or 6-membered N/O/S-heterocyclyl (≤3 heteroatoms); X = CO, CH2 or chemical bond; Y = 5- or 6-membered N/O/S-heteroaryl (≤3 heteroatoms) optionally substituted by halogen, OH, CN, carboxy, NO2, CF3, CF3O, etc.; R2 = H, alkyl or cycloalkyl optionally substituted by OH, alkoxy, alkylamino, Ph, biphenyl, naphthyl, etc.; R1 and R2 may form ring; R3 = certain substituted substituted CONH2 or NH2]. Approx. 310 specific examples of I were prepared and/or claimed. For example, EDCI-mediated coupling of acid II with (2S)-phenylethylamine provided claimed compound III in 89% yield. Rat Langendorff-heart studies of 9 claimed compds. disclosed compound III reduced perfusion pressure at 0.001 μM.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:185069 CAPLUS
DN 136:232117
TI Substituted phenylcyclohexanecarboxylic acid amides and their use in treating cardiovascular disease
IN Bischoff, Erwin; Krahn, Thomas; Mueller, Stephan-Nicholas; Paulsen, Holger; Schuhmacher, Joachim; Steinhagen, Henning; Thielemann, Wolfgang
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002020472	A1	20020314	WO 2001-EP9938	20010829

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
DE 2000-10044792A 20000911

DE 10044792	A1	20020404	DE 2000-10044792 20000911
AU 2002012176	A5	20020322	AU 2002-12176 20010829
			DE 2000-10044792A 20000911
			WO 2001-EP9938 W 20010829
EP 1318977	A1	20030618	EP 2001-980296 20010829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
			DE 2000-10044792A 20000911
			WO 2001-EP9938 W 20010829
BR 2001013814	A	20030708	BR 2001-13814 20010829
			DE 2000-10044792A 20000911
			WO 2001-EP9938 W 20010829
JP 2004508350	T2	20040318	JP 2002-525095 20010829
			DE 2000-10044792A 20000911
			WO 2001-EP9938 W 20010829
US 2003008881	A1	20030109	US 2001-943325 20010830
US 6649616	B2	20031118	

DE 2000-10044792A 20000911

OS MARPAT 136:232117

IT **403600-13-5P 403600-21-5P 403600-36-2P 403600-57-7P 403600-63-5P 403600-69-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted phenylcyclohexanecarboxylic acid amides and their use in treating cardiovascular disease)

RN 403600-13-5 CAPLUS

CN 4-Morpholinecarboxamide, N-[[4-[(1R,2R)-2-[[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-21-5 CAPLUS

CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[(dimethylamino)carbonyl]phenylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-36-2 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[(dimethylamino)carbonyl](4-fluorophenyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-57-7 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[(diethylamino)carbonyl]-2-pyridinylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-63-5 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[[ethyl(2-hydroxyethyl)amino]carbonyl](4-fluorophenyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-4-fluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-69-1 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[[ethyl(2-hydroxyethyl)amino]carbonyl]phenylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **403600-88-4P 403600-89-5P 403601-27-4P 403601-34-3P 403601-35-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted phenylcyclohexanecarboxylic acid amides and their use in treating cardiovascular disease)
RN 403600-88-4 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[(acetyloxy)methyl]phenyl]cycloh exyl]carbonyl]amino]-4-fluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-89-5 CAPLUS
CN Benzeneacetamide, 4-fluoro-α-[[[(1R,2R)-2-[4-(hydroxymethyl)phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-27-4 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-(aminomethyl)phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-34-3 CAPLUS

CN Propanedioic acid, [[4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-35-4 CAPLUS
CN Benzenepropanoic acid, 4-[(1R,2R)-2-[[[(1R)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **403600-18-0P 403600-20-4P 403600-24-8P**
403600-25-9P 403600-27-1P 403600-28-2P
403600-30-6P 403600-32-8P 403600-33-9P
403600-34-0P 403600-37-3P 403600-38-4P
403600-39-5P 403600-40-8P 403600-41-9P
403600-43-1P 403600-44-2P 403600-45-3P
403600-46-4P 403600-47-5P 403600-48-6P
403600-49-7P 403600-50-0P 403600-51-1P
403600-52-2P 403600-53-3P 403600-54-4P
403600-55-5P 403600-56-6P 403600-70-4P
403600-71-5P 403600-72-6P 403600-73-7P

403600-74-8P 403600-75-9P 403600-76-0P
403600-77-1P 403600-78-2P 403600-79-3P
403600-80-6P 403600-81-7P 403600-82-8P
403600-83-9P 403600-84-0P 403600-85-1P
403600-90-8P 403600-91-9P 403600-92-0P
403600-93-1P 403600-94-2P 403600-95-3P
403600-96-4P 403600-97-5P 403600-98-6P
403600-99-7P 403601-00-3P 403601-01-4P
403601-02-5P 403601-03-6P 403601-04-7P
403601-05-8P 403601-06-9P 403601-07-0P
403601-08-1P 403601-09-2P 403601-10-5P
403601-11-6P 403601-12-7P 403601-13-8P
403601-14-9P 403601-15-0P 403601-16-1P
403601-17-2P 403601-18-3P 403601-20-7P
403601-21-8P 403601-22-9P 403601-25-2P
403601-28-5P 403601-29-6P 403601-30-9P
403601-31-0P 403601-36-5P 403601-37-6P
403601-38-7P 403660-70-8P 403660-71-9P
403660-72-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted phenylcyclohexanecarboxylic acid amides and their use in treating cardiovascular disease)

RN 403600-18-0 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[(acetyl-2-pyridinylamino)methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-20-4 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[(dimethylamino)carbonyl]phenylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-4-fluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-24-8 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[[4-[(1R,2R)-2-[[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-25-9 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[[4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-27-1 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[(diethylamino)carbonyl]phenyl amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-28-2 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[(diethylamino)carbonyl]phenyl amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-4-fluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-30-6 CAPLUS
CN 4-Morpholinecarboxamide, N-[[4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]-N-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-32-8 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[(dimethylamino)carbonyl](4-fluorophenyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-4-fluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-33-9 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[(diethylamino)carbonyl](4-fluorophenyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-4-fluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-34-0 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[(diethylamino)carbonyl](4-fluorophenyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-37-3 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[cyclopropyl[(dimethylamino)car

bonyl]amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-38-4 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[cyclopropyl[(dimethylamino)carbonyl]amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-4-fluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-39-5 CAPLUS
CN 3-Pyridineacetamide, α-[[[(1R,2R)-2-[4-[[cyclopropyl[(dimethylamino)carbonyl]amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-40-8 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[[(2-methoxyethyl)methylamino]carbonyl]phenylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-41-9 CAPLUS
CN Benzeneacetamide, 4-fluoro-α-[[[(1R,2R)-2-[4-[[[[(2-methoxyethyl)methylamino]carbonyl]phenylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-43-1 CAPLUS
CN 3-Pyridineacetamide, α-[[[(1R,2R)-2-[4-[[[[(2-methoxyethyl)methylamino]carbonyl]phenylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-44-2 CAPLUS
CN 3-Pyridineacetamide, α-[[[(1R,2R)-2-[4-[[[(dimethylamino)carbonyl](4-fluorophenyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-45-3 CAPLUS
CN 3-Pyridineacetamide, α-[[[(1R,2R)-2-[4-[[[(diethylamino)carbonyl](4-fluorophenyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-46-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[[4-[(1R,2R)-2-[[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]-N-(4-fluorophenyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-47-5 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[[4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-48-6 CAPLUS
CN 3-Pyridineacetamide, α-[[[(1R,2R)-2-[4-[[(4-fluorophenyl)(1-pyrrolidinylcarbonyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-49-7 CAPLUS
CN 4-Morpholinecarboxamide, N-[[4-[(1R,2R)-2-[[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-50-0 CAPLUS
CN 4-Morpholinecarboxamide, N-[[4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-51-1 CAPLUS
CN 4-Morpholinecarboxamide, N-[[4-[(1R,2R)-2-[[[(1S)-2-amino-2-oxo-1-(3-pyridinyl)ethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-52-2 CAPLUS
CN 3-Pyridineacetamide, α-[[[(1R,2R)-2-[4-[[[(dimethylamino)carbonyl]ethylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-53-3 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[(dimethylamino)carbonyl]ethylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-4-fluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-54-4 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[(dimethylamino)carbonyl]ethyl amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-55-5 CAPLUS
CN 3-Pyridineacetamide, α-[[[(1R,2R)-2-[4-[[[(diethylamino)carbonyl]-2-pyridinylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-56-6 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[(diethylamino)carbonyl]-2-pyridinylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-4-fluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-70-4 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[[bis(2-hydroxyethyl)amino]carbonyl]phenylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-71-5 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[[(2-hydroxyethyl)amino]carbonyl]phenylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-72-6 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[(2-hydroxyethyl)[(phenylamino)carbonyl]amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-73-7 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[[bis(2-hydroxyethyl)amino]carbonyl]phenylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-4-fluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-74-8 CAPLUS
CN 3-Pyridineacetamide, α-[[[(1R,2R)-2-[4-[[[[bis(2-hydroxyethyl)amino]carbonyl]phenylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-75-9 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[[ethyl(2-hydroxyethyl)amino]carbonyl]phenylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-4-fluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-76-0 CAPLUS
CN 3-Pyridineacetamide, α-[[[(1R,2R)-2-[4-[[[[ethyl(2-hydroxyethyl)amino]carbonyl]phenylamino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-77-1 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[(4-fluorophenyl)[[(2-hydroxyethyl)methylamino]carbonyl]amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-78-2 CAPLUS
CN Benzeneacetamide, 4-fluoro-α-[[[(1R,2R)-2-[4-[[(4-fluorophenyl)[[(2-hydroxyethyl)methylamino]carbonyl]amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-79-3 CAPLUS
CN 3-Pyridineacetamide, α-[[[(1R,2R)-2-[4-[[(4-fluorophenyl)[[(2-hydroxyethyl)methylamino]carbonyl]amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-80-6 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[[ethyl(2-hydroxyethyl)amino]carbonyl](4-fluorophenyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-81-7 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[[bis(2-hydroxyethyl)amino]carbonyl](4-fluorophenyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-82-8 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[[[bis(2-hydroxyethyl)amino]carbonyl](4-fluorophenyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-4-fluoro-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-83-9 CAPLUS
CN 3-Pyridineacetamide, α-[[[(1R,2R)-2-[4-[[[[bis(2-hydroxyethyl)amino]carbonyl](4-fluorophenyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-84-0 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[ethyl[[ethyl(2-hydroxyethyl)amino]carbonyl]amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-85-1 CAPLUS
CN Benzeneacetamide, α-[[[(1R,2R)-2-[4-[[ethyl[[(2-hydroxyethyl)methylamino]carbonyl]amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-90-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-hydroxy-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-91-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-(2-hydroxyethyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-92-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-(2-hydroxyethyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-93-1 CAPLUS
CN Carbamic acid, butyl-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-94-2 CAPLUS
CN Carbamic acid, (2-methylpropyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-95-3 CAPLUS
CN Carbamic acid, (3-ethoxypropyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-96-4 CAPLUS
CN Carbamic acid, [2-(diethylamino)ethyl]-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-97-5 CAPLUS
CN Carbamic acid, cycloheptyl-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-98-6 CAPLUS
CN Carbamic acid, (cyclohexylmethyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403600-99-7 CAPLUS
CN Carbamic acid, (cyclopropylmethyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-00-3 CAPLUS
CN Carbamic acid, tricyclo[3.3.1.13,7]dec-1-yl-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-01-4 CAPLUS
CN Carbamic acid, cyclopentyl-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-02-5 CAPLUS
CN Carbamic acid, (1,1-dimethylethyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-03-6 CAPLUS
CN Carbamic acid, (4-pyridinylmethyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-04-7 CAPLUS
CN Carbamic acid, (1-methylethyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-05-8 CAPLUS
CN Carbamic acid, (3,3,3-trifluoropropyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-06-9 CAPLUS
CN Carbamic acid, (1-ethylpropyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-07-0 CAPLUS
CN Carbamic acid, [3-(2-methoxyethoxy)propyl]-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-08-1 CAPLUS
CN Carbamic acid, [3-(1H-1,2,4-triazol-1-yl)propyl]-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-09-2 CAPLUS
CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-10-5 CAPLUS
CN 4-Morpholinecarboxylic acid, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-11-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-12-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-ethyl-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-13-8 CAPLUS
CN Carbamic acid, [2-hydroxy-1-(hydroxymethyl)ethyl]-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-14-9 CAPLUS
CN Carbamic acid, 1-pyrrolidinyl-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-15-0 CAPLUS
CN Carbamic acid, bis(2-hydroxyethyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-16-1 CAPLUS
CN Carbamic acid, 4-morpholinyl-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-17-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-hydroxy-, [4-[(1R,2R)-2-[[[(1S)-2-amino-2-oxo-1-(3-pyridinyl)ethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-18-3 CAPLUS
CN Carbamic acid, bis(2-hydroxyethyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-2-oxo-1-(3-pyridinyl)ethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-20-7 CAPLUS
CN Carbamic acid, (1,1-dimethylethyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-21-8 CAPLUS
CN Carbamic acid, ethyl-, [4-[(1R,2R)-2-[[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-22-9 CAPLUS
CN 4-Morpholinecarboxylic acid, [4-[(1R,2R)-2-[[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-25-2 CAPLUS
CN Carbamic acid, [[4-[2-[[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-28-5 CAPLUS

CN Benzeneacetamide, α-[[[2-[4-[[(4-fluorobenzoyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-29-6 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[[(methoxyacetyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-30-9 CAPLUS
CN 4-Pyridinecarboxamide, N-[[4-[2-[[[(1S)-2-amino-2-oxo-1-phenylethyl]amino]carbonyl]cyclohexyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-31-0 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[[(cyclopropylcarbonyl)amino]methyl]phenyl]cyclohexyl]carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-36-5 CAPLUS
CN Benzenepropanamide, 4-[(1R,2R)-2-[[[(1R)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-37-6 CAPLUS
CN Benzenepropanamide, 4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403601-38-7 CAPLUS
CN Benzenepropanamide, 4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-

oxoethyl]amino]carbonyl]cyclohexyl]-N,N-bis(2-methoxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403660-70-8 CAPLUS
CN Carbamic acid, (2,5-dimethylcyclopentyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403660-71-9 CAPLUS
CN Carbamic acid, (4-hydroxycyclohexyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403660-72-0 CAPLUS
CN Carbamic acid, (4-hydroxycyclohexyl)-, [4-[(1R,2R)-2-[[[(1S)-2-amino-2-oxo-1-(3-pyridinyl)ethyl]amino]carbonyl]cyclohexyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB Title compds. I [D = (un)substituted C6H4, thiophene-2,5-diyl; A = O, (un)substituted NH, CH2; R1 = H, alkyl, hydroxyalkyl, alkoxyalkyl,

Siegfried; Gerdes, Christoph; Domdey-Bette, Anke; Gruetzmann, Rudi; Lohmer, Stefan; Wohlfeil, Stefan; et al.
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 725064	A1	19960807	EP 1996-100760	19960119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				DE 1995-19503160A	19950201
	DE 19503160	A1	19960808	DE 1995-19503160	19950201
	TW 448176	B	20010801	TW 1996-85100684	19960122
				DE 1995-19503160A	19950201
	RO 117256	B1	20011228	RO 1996-152	19960126
				DE 1995-19503160A	19950201
	CA 2168317	AA	19960802	CA 1996-2168317	19960129
				DE 1995-19503160A	19950201
	JP 08253453	A2	19961001	JP 1996-33174	19960129
				DE 1995-19503160A	19950201
	IL 116931	A1	20000601	IL 1996-116931	19960129
				DE 1995-19503160A	19950201
	FI 9600425	A	19960802	FI 1996-425	19960130
				DE 1995-19503160A	19950201
	AU 9642240	A1	19960808	AU 1996-42240	19960130
	AU 710235	B2	19990916		
				DE 1995-19503160A	19950201
	BG 63044	B1	20010228	BG 1996-100326	19960130
				DE 1995-19503160A	19950201
	BG 103820	A	20010928	BG 1999-103820	19960130
				DE 1995-19503160A	19950201
	NO 9600414	A	19960802	NO 1996-414	19960131
				DE 1995-19503160A	19950201
	ZA 9600725	A	19960820	ZA 1996-725	19960131
				DE 1995-19503160A	19950201
	RU 2158261	C2	20001027	RU 1996-101800	19960131
				DE 1995-19503160A	19950201
	CN 1137380	A	19961211	CN 1996-102574	19960201
				DE 1995-19503160A	19950201
	US 5935983	A	19990810	US 1997-960075	19971024
				DE 1995-19503160A	19950201
				US 1996-588477	B119960118

OS MARPAT 125:221843
IT **181130-37-0P 181130-38-1P 181130-39-2P**
181130-40-5P 181130-41-6P 181130-42-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzylimidazole derivs. for the treatment of vascular restenosis)
RN 181130-37-0 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[[2-(1-methylethyl)-1H-benzimidazol-1-yl]methyl]phenyl]cyclohexyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 181130-38-1 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[(2-cyclopropyl-1H-benzimidazol-1-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 181130-39-2 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[[2-(1-methylethyl)-3H-imidazo[4,5-b]pyridin-3-yl]methyl]phenyl]cyclohexyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 181130-40-5 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[(2-ethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 181130-41-6 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[(2-ethyl-1H-benzimidazol-1-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 181130-42-7 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[(2-phenyl-1H-benzimidazol-1-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



GI



I

AB The title compds. [I; D = CH, N; R1 = Ph, cycloalkyl, (un)branched alkyl; R2 = (un)branched alkoxycarbonyl, CH2OH, CONH2], useful for the treatment of vascular restenosis, are prepared Thus, I (D = N, R1 = CHMe2, R2 = CONH2; * * cyclohexyl ring bonding is trans) was prepared and demonstrated a IC50 of 0.01 nM for the inhibition of rat aorta smooth muscle proliferation.

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:560541 CAPLUS
DN 125:221572
TI Preparation of substituted 3-benzylindole antiatherosclerotics
IN Mueller-Gliemann, Matthias; Mueller, Ulrich; Beuck, Martin; Zaiss,

Sigfried; Gerdes, Christoph; Domdey-Better, Anke; Gruetzmann, Rudi; Lohmer, Stefan; Wohlfeil, Stefan; et al.
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 725061	A1	19960807	EP 1996-100761	19960119
	EP 725061	B1	20000607		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	DE 19513716	A1	19960808	DE 1995-19513716	19950411
				DE 1995-19503159A1	19950201
	HR 960015	B1	20001231	HR 1996-960015	19960115
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	AT 193701	E	20000615	AT 1996-100761	19960119
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	ES 2148600	T3	20001016	ES 1996-100761	19960119
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	PT 725061	T	20001130	PT 1996-96100761	19960119
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	JP 08253451	A2	19961001	JP 1996-30123	19960125
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	CA 2168320	AA	19960802	CA 1996-2168320	19960129
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	FI 9600424	A	19960802	FI 1996-424	19960130
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	AU 9642241	A1	19960808	AU 1996-42241	19960130
	AU 708784	B2	19990812		
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	IL 116956	A1	20000217	IL 1996-116956	19960130
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	NO 9600413	A	19960802	NO 1996-413	19960131
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	ZA 9600726	A	19960820	ZA 1996-726	19960131
				DE 1995-19503159A	19950201
	RU 2162842	C2	20010210	RU 1996-101801	19960131
				DE 1995-19503159A	19950201
	CN 1137520	A	19961211	CN 1996-102575	19960201
	CN 1067987	B	20010704		
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	GR 3034245	T3	20001229	GR 2000-401932	20000823
				DE 1995-19503159A	19950201

DE 1995-19513716A 19950411

OS MARPAT 125:221572

IT **181070-80-4P 181070-82-6P 181228-88-6P 181228-90-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 3-benzylindole antiatherosclerotics)

RN 181070-80-4 CAPLUS

CN Benzeneacetamide, α-[[[2-[4-[(2-phenyl-1H-indol-3-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 181070-82-6 CAPLUS

CN Benzeneacetamide, α-[[[2-[4-[(1-methyl-2-phenyl-1H-indol-3-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]-, [1α(S*),2β]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 181228-88-6 CAPLUS

CN Benzeneacetamide, α-[[[2-[4-[(2-phenyl-1H-indol-3-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]-, [1α(R*),2β]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 181228-90-0 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[(1-methyl-2-phenyl-1H-indol-3-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]-, [1α(R*),2β]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



I



II

AB The title compds. [I; R1 = Ph, cycloalkyl, (un)branched alkyl; R2 = H, (un)branched alkyl; R3 = CONH2, CH2OH], useful for the treatment of atherosclerosis or restenosis, are prepared Thus, II, prepared from phenylglycinamide, demonstrated a IC50 of 0.052 nM against the proliferation of pig aorta smooth muscle.

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:94905 CAPLUS
DN 122:56057
TI [(Imidazo[4,5-b]pyridinylmethyl)phenyl]cyclohexanecarboxylates as angiotensin antagonists
IN Mueller, Ulrich; Dressel, Juergen; Fey, Peter; Hanko, Rudolf; Huebsch, Walter; Kraemer, Thomas; Mueller-Gliemann, Matthias; Beuck, Martin; Kazda, Stanislav; et al.
PA Bayer A.-G., Germany

SO Ger. Offen., 29 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4304455	A1	19940818	DE 1993-4304455	19930215
	AU 9454807	A1	19940818	AU 1994-54807	19940131
	AU 672262	B2	19960926		
				DE 1993-4304455A	19930215
	EP 611767	A1	19940824	EP 1994-101543	19940202
	EP 611767	B1	20000906		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				DE 1993-4304455A	19930215
	AT 196141	E	20000915	AT 1994-101543	19940202
				DE 1993-4304455A	19930215
	ES 2151908	T3	20010116	ES 1994-101543	19940202
				DE 1993-4304455A	19930215
	PT 611767	T	20010228	PT 1994-94101543	19940202
				DE 1993-4304455A	19930215
	US 5395840	A	19950307	US 1994-193835	19940208
				DE 1993-4304455A	19930215
	CA 2115536	AA	19940816	CA 1994-2115536	19940211
				DE 1993-4304455A	19930215
	FI 9400659	A	19940816	FI 1994-659	19940211
				DE 1993-4304455A	19930215
	IL 108625	A1	19970930	IL 1994-108625	19940211
				DE 1993-4304455A	19930215
	PL 177834	B1	20000131	PL 1994-302213	19940211
				DE 1993-4304455A	19930215
	NO 9400506	A	19940816	NO 1994-506	19940214
				DE 1993-4304455A	19930215
	ZA 9400984	A	19940824	ZA 1994-984	19940214
				DE 1993-4304455A	19930215
	JP 06293741	A2	19941021	JP 1994-37543	19940214
				DE 1993-4304455A	19930215
	RU 2119480	C1	19980927	RU 1994-4975	19940214
				DE 1993-4304455A	19930215
	CN 1108257	A	19950913	CN 1994-101553	19940215
	CN 1057085	B	20001004		
				DE 1993-4304455A	19930215
	CZ 289096	B6	20011114	CZ 1994-329	19940215
				DE 1993-4304455A	19930215
	GR 3034957	T3	20010228	GR 2000-402660	20001130
				DE 1993-4304455A	19930215

OS MARPAT 122:56057
IT **158098-22-7P 158189-62-9P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [[(imidazopyridinyl)methyl]phenyl]cyclohexanecarboxylates as angiotensin antagonists)
RN 158098-22-7 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[(2-cyclopropyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]-, [1α(R*),2β]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 158189-62-9 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[(2-cyclopropyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]-, [1α(S*),2β]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



GI For diagram(s), see printed CA Issue.
AB The title compds., [(imidazolylmethyl)phenyl]cyclohexanecarboxylate derivs. and [(pyrrolylmethyl)phenyl]cyclohexanecarboxylate derivs. I (A = H, aryl, etc.; B, D = substituent; BD = fused ring fragment; E = nitrogen, methine; L = H, halo, nitro, etc.; T = carboxy or amide function) were disclosed as agents for the treatment of arterial hypertonia and atherosclerosis. I are antihypertensives (angiotensin II antagonists). An example compound, the [(imidazo[4,5-b]pyridinylmethyl)phenyl]cyclohexanec arboxylate II was prepared

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	44.56	200.19

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.24	-6.24

STN INTERNATIONAL LOGOFF AT 12:55:17 ON 28 APR 2004

AB Title compds., e.g. I, were prepared for use in treating ischemic brain **diseases** in humans or animals. Thus I [X = N, X1 = O (II)] was prepared in six steps, starting from 2,3-diaminopyridine, glycolic acid, (1R,2R)-2-(4-bromomethylphenyl)cyclohexane-1-carboxylic acid tert-Bu ester (preparation given), and (S)-phenylglycinamide hydrochloride. Similarly prepared was I [X = C, X1 = N(Me) (III)]. In in vivo (binding of calf cortex adenosine transport protein) compds. II and III had Ki = 2 nM. In in vitro tests of rat brain reperfusion injury, II and III were effective at 0.001 mg/kg, reducing infarct volume 81-91% of control.

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:397335 CAPLUS
DN 127:17433
TI Cyclopentyl tachykinin receptor antagonists
IN Finke, Paul E.; Maccoss, Malcom; Meurer, Laura C.; Mills, Sander G.; Caldwell, Charles G.; Chen, Ping; Durette, Philippe L.; Hale, Jeffery; Holson, Edward; Kopka, Ihor; Robichaud, Albert
PA Merck and Co., Inc., USA; Finke, Paul E.; Maccoss, Malcolm; Meurer, Laura C.; Mills, Sander G.; Caldwell, Charles G.; Chen, Ping; Durette, Philippe L.; Hale, Jeffrey; et al.
SO PCT Int. Appl., 343 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9714671	A1	19970424	WO 1996-US16489	19961015
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
			US 1995-5558P	P 19951018
			GB 1996-2853	A 19960213
AU 9710497	A1	19970507	AU 1997-10497	19961015
AU 722883	B2	20000810		
			US 1995-5558P	P 19951018
			GB 1996-2853	A 19960213
			WO 1996-US16489W	19961015
EP 858444	A1	19980819	EP 1996-941315	19961015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
			US 1995-5558P	P 19951018
			GB 1996-2853	A 19960213
			WO 1996-US16489W	19961015
JP 2002534955	T2	20021015	JP 1997-515929	19961015
			US 1995-5558P	P 19951018
			GB 1996-2853	A 19960213
			WO 1996-US16489W	19961015

PATENT FAMILY INFORMATION:
FAN 1997:381012

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 9715305 A1 19970501 WO 1996-US16871 19961022
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
US 1995-5869P P 19951026
GB 1996-2853 A 19960213

AU 9674637 A1 19970515 AU 1996-74637 19961022
US 1995-5869P P 19951026
GB 1996-2853 A 19960213
WO 1996-US16871W 19961022

US 5932559 A 19990803 US 1998-51948 19980423
GB 1996-2853 A 19960213
WO 1996-US16871W 19961022

OS MARPAT 127:17433

IT **190271-06-8P 190271-24-0P 190271-33-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of cyclopentyl derivs. as tachykinin receptor antagonists)

RN 190271-06-8 CAPLUS

CN Cyclohexanecarboxylic acid, 3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190271-24-0 CAPLUS

CN Cyclohexanecarboxylic acid, 3-[[[2-methoxy-5-(1H-tetrazol-1-yl)phenyl]methyl][(phenylmethoxy)carbonyl]amino]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190271-33-1 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **190269-13-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of cyclopentyl derivs. as tachykinin receptor antagonists)
RN 190269-13-7 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[[[2-methoxy-5-(1H-tetrazol-1-yl)phenyl]methyl]amino]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI

etc.; Z1 = bond or (O- or S-interrupted, -initiated, or -terminated) alkylene] were prepared Thus, Me 3-oxo-6-phenyl-1-cyclohexenecarboxylate was treated with a lipase and the product levorotatory ester cyclocondensed with PhCH2N(CH2OBu)CH2SiMe3 to give (-)-(3aRS,4RS,7aSR)-2-benzyl-7-oxo-4-phenylperhydroisoindole-3a-carboxylic acid Me ester which was condensed with 4-MeC6H4MgBr and the product cyclized to give, in 3 addnl. steps., title compound (-)-(3aRS,4SR,9SR,9aRS)-II.

L5 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:460422 CAPLUS
DN 131:102272
TI Preparation of ethanoisoindoles as farnesyl transferase inhibitors
IN Dereu, Norbert; Mailliet, Patrick; Sounigo-Thompson, Fabienne
PA Rhone-Poulenc Rorer S.A., Fr.
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9933834	A1	19990708	WO 1998-FR2804	19981221
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
				FR 1997-16335 A	19971223
				US 1998-73800P P	19980205
	FR 2772764	A1	19990625	FR 1997-16335	19971223
	FR 2772764	B1	20000114		
	CA 2315144	AA	19990708	CA 1998-2315144	19981221
				FR 1997-16335 A	19971223
				US 1998-73800P P	19980205
				WO 1998-FR2804 W	19981221
	AU 9917675	A1	19990719	AU 1999-17675	19981221
				FR 1997-16335 A	19971223
				US 1998-73800P P	19980205
				WO 1998-FR2804 W	19981221
	EP 1042329	A1	20001011	EP 1998-962528	19981221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
				FR 1997-16335 A	19971223
				US 1998-73800P P	19980205
				WO 1998-FR2804 W	19981221
	JP 2001527078	T2	20011225	JP 2000-526514	19981221
				FR 1997-16335 A	19971223
				US 1998-73800P P	19980205
				WO 1998-FR2804 W	19981221
	ZA 9811787	A	19990629	ZA 1998-11787	19981222
				FR 1997-16335 A	19971223

OS MARPAT 131:102272
IT **230306-92-0P 230307-11-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ethanoisoindoles as farnesyl transferase inhibitors)

RN 230306-92-0 CAPLUS
CN Cyclohexanecarboxylic acid, 1-hydroxy-5-oxo-2-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 230307-11-6 CAPLUS
CN Cyclohexanecarboxylic acid, 1-hydroxy-2-(1H-indol-3-yl)-5-oxo- (9CI) (CA INDEX NAME)



GI



I



II

AB Title compds. [I; R = CO2H, alkoxycarbonyl, (di)alkylcarbamoyl, etc.; R1R2 = atoms to complete a heterocyclic or heteroarom. ring; R3 = COZR5; R4 = (un)substituted (hetero)aryl; R5 = (un)substituted Ph; Z = CH2, alkenylidene, cycloalkylidene] were prepared Thus, Me 6-(2-thienyl)-3-oxocyclohexene-1-carboxylate (preparation given) was cyclocondensed with BuOCH2N(CH2SiMe3)CH2Ph and the product condensed with PhMgBr to give, after cyclization, deprotection, amidation, and saponification steps, title compound (3aRS,4SR,8SR,8aRS)-II. Data for biol. activity of I were given.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:485041 CAPLUS
DN 129:122567
TI Preparation of ethanobenzoisoindole derivatives as farnesyl transferase inhibitors
IN Bourzat, Jean-Dominique; Commercon, Alain; Dereu, Norbert; Mailliet, Patrick; Sounigo-Thompson, Fabienne; Martin, Jean-Paul; Capet, Marc; Cheve, Michel
PA Rhone-Poulenc Rorer S.A., Fr.
SO PCT Int. Appl., 260 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9829390	A1	19980709	WO 1997-FR2407	19971223
	W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				FR 1996-16206 A	19961230
	FR 2757855	A1	19980703	FR 1996-16206	19961230
	FR 2757855	B1	19990129		
	AU 9856694	A1	19980731	AU 1998-56694	19971223
	AU 741921	B2	20011213		
				FR 1996-16206 A	19961230
				WO 1997-FR2407 W	19971223
	EP 948483	A1	19991013	EP 1997-953000	19971223
	EP 948483	B1	20020313		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
				FR 1996-16206 A	19961230
				WO 1997-FR2407 W	19971223
	CN 1242000	A	20000119	CN 1997-180944	19971223
				FR 1996-16206 A	19961230
	BR 9714498	A	20000321	BR 1997-14498	19971223
				FR 1996-16206 A	19961230
				WO 1997-FR2407 W	19971223
	NZ 336042	A	20001222	NZ 1997-336042	19971223
				FR 1996-16206 A	19961230
				WO 1997-FR2407 W	19971223
	JP 2001509147	T2	20010710	JP 1998-529686	19971223
				FR 1996-16206 A	19961230
				WO 1997-FR2407 W	19971223
	AT 214367	E	20020315	AT 1997-953000	19971223
				FR 1996-16206 A	19961230
				WO 1997-FR2407 W	19971223
	PT 948483	T	20020830	PT 1997-97953000	19971223
				FR 1996-16206 A	19961230
	ES 2172033	T3	20020916	ES 1997-953000	19971223
				FR 1996-16206 A	19961230
	US 6013662	A	20000111	US 1997-999408	19971229
				FR 1996-16206 A	19961230

ZA 9711734	A	19980625	ZA 1997-11734 19971230
			FR 1996-16206 A 19961230
NO 9903225	A	19990824	NO 1999-3225 19990629
			FR 1996-16206 A 19961230
			WO 1997-FR2407 W 19971223
US 6124465	A	20000926	US 1999-346540 19990702
			US 1997-66884P P 19971125
			US 1997-999408 A319971229
US 6218406	B1	20010417	US 1999-346303 19990702
			FR 1996-16206 A 19961230
			US 1997-66884P P 19971125
			US 1997-999408 A319971229

OS MARPAT 129:122567

IT **210284-97-2P 210285-06-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of ethanobenzoisoindole derivs. as farnesyl transferase inhibitors)

RN 210284-97-2 CAPLUS

CN Cyclohexanecarboxylic acid, 1-hydroxy-2-(2-methoxyphenyl)-5-oxo- (9CI) (CA INDEX NAME)



RN 210285-06-6 CAPLUS

CN Cyclohexanecarboxylic acid, 1-hydroxy-2-methyl-5-oxo-2-phenyl-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



I



II

AB Approx. 100 title compds. I were prepared and tested [wherein Ar = substituted or condensed Ph radical, or polycyclic or heterocyclic aromatic radical; R = radical of general formula (CH2)mX1(CH2)nZ in which X1 = bond, O, S; m = 0, 1; n = 0, 1, 2; the CH2 radicals can be substituted; Z = CO2H, COOR6 (R6 = alkyl), CONR7R8 [R7 = H or alkyl, and R8 = H, OH, arylsulfonyl, heterocyclyl, (un)substituted amino, alkoxy, alkyl, PO(OR9)2 (R9 = H or alkyl), NHCOT [T = H or (un)substituted alkyl], or pyridiniomethyl]; R1, R2 = H, halo, alkyl, (un)substituted alkoxy, alkylthio, alkoxycarbonyl; or ortho R1 and R2 may form (un)substituted heterocycle with 1 or 2 heteroatoms; R3, R4 = H, halo, alkyl, alkylene, alkoxy, alkylthio, carboxy, or alkoxycarbonyl; R5 = H, alkyl, alkylthio; X = O, S, NH, CO, CH2, vinyldiyl, alkene-1,1-diyl, or cycloalkane-1,1-diyl; Y = O or S], including racemates, optical isomers, and salts. The compds. are inhibitors of farnesyl transferase which show remarkable tumoricidal and anti-leukemic properties. For instance, (3aRS,4SR,7aRS)-Me 2-benzyl-7-oxo-4-phenyloctahydroisoindole-3a-carboxylate underwent a sequence of: (1) Grignard reaction with 3-ClC6H4Br, (2) alkylative cyclization of the resulting alc. in the presence of CF3SO3H, (3) N-debenzylation using vinyl chloroformate, (4) acidic removal of the residual N-vinyloxycarbonyl group, (5) N-acylation using 2-MeOC6H4C(:CH2)CO2H, and (6) alkaline hydrolysis of the Me ester, to give title compound II. In an in vitro assay for farnesylation of a K-ras substrate, II inhibited farnesyl transferase with an IC50 of 0.005 μM.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:306975 CAPLUS
DN 129:15967
TI Preparation of arylcycloalkanes as tachykinin receptor antagonists.
IN Caldwell, Charles G.; Chen, Ping; Durette, Philippe L.; Finke, Paul; Hale, Jeffrey; Holson, Edward; Kopka, Ihor; Maccoss, Malcolm; Meurer, Laura;

Mills, Sander G.; Robichaud, Albert
PA Merck and Co., Inc., USA
SO U.S., 109 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5750549	A	19980512	US 1996-730277	19961015
			US 1996-730277	19961015

OS MARPAT 129:15967
IT **190269-13-7P 190271-06-8P 190271-24-0P**
190271-33-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylcycloalkanes as tachykinin receptor antagonists)
RN 190269-13-7 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[[[2-methoxy-5-(1H-tetrazol-1-yl)phenyl]methyl]amino]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190271-06-8 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190271-24-0 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[[[2-methoxy-5-(1H-tetrazol-1-yl)phenyl]methyl][(phenylmethoxy)carbonyl]amino]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190271-33-1 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB Title compds. [I; R3 = H, alkoxy, phenylalkoxy, Ph, cyano, halo, amino, (substituted) alkyl, null; R6-R8 = H, alkoxy, halo, (substituted) alkyl, OH, cyano, CF3, NO2, heterocyclyl, etc.; R11-R13 = H, (substituted) alkyl, halo, cyano, CF3, NO2, OH, alkoxy, etc.; A = Ph, benzofuranyl, benzothiophenyl, benzothiazoyl, indolyl, imidazolyl, oxadiazolyl, pyridyl, pyrimidyl, quinolinyl, thiazolyl, thienyl, thiophenyl, dihydrobenzofuranyl; Q = H, alkyl; W = O, NH, alkylimino, NHCO, alkyliminocarbonyl; X = H, alkyl; Y = bond, (substituted) alkyl; Z = NR15, CONR15, SO2NR15, SO2, CO2R15, CH2OR15, null; R15 = H, (substituted) alkyl; n = 1-3; with provisos], were prepared Thus, Me 3(SR)-hydroxy-2(RS)-phenylcyclopentane-1(RS)-carboxylate (preparation given) was treated with 3,5-bis(trifluoromethyl)benzyl bromide and NaH in DMF to give Me

3(SR)-[3,5-bis(trifluoromethyl)phenylmethoxy]-2(RS)-phenylcyclopentane-1(RS)-carboxylate. I showed intrinsic tachykinin receptor antagonist activity in the range 0.05-10 μM.

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:397335 CAPLUS
DN 127:17433
TI Cyclopentyl tachykinin receptor antagonists
IN Finke, Paul E.; Maccoss, Malcom; Meurer, Laura C.; Mills, Sander G.; Caldwell, Charles G.; Chen, Ping; Durette, Philippe L.; Hale, Jeffery; Holson, Edward; Kopka, Ihor; Robichaud, Albert
PA Merck and Co., Inc., USA; Finke, Paul E.; Maccoss, Malcolm; Meurer, Laura C.; Mills, Sander G.; Caldwell, Charles G.; Chen, Ping; Durette, Philippe L.; Hale, Jeffrey; et al.
SO PCT Int. Appl., 343 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9714671	A1	19970424	WO 1996-US16489	19961015
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
				US 1995-5558P	P 19951018
				GB 1996-2853	A 19960213
	AU 9710497	A1	19970507	AU 1997-10497	19961015
	AU 722883	B2	20000810		
				US 1995-5558P	P 19951018
				GB 1996-2853	A 19960213
				WO 1996-US16489W	19961015
	EP 858444	A1	19980819	EP 1996-941315	19961015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
				US 1995-5558P	P 19951018
				GB 1996-2853	A 19960213
				WO 1996-US16489W	19961015
	JP 2002534955	T2	20021015	JP 1997-515929	19961015
				US 1995-5558P	P 19951018
				GB 1996-2853	A 19960213
				WO 1996-US16489W	19961015

PATENT FAMILY INFORMATION:
FAN 1997:381012

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9715305	A1	19970501	WO 1996-US16871	19961022
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,				

IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

			US 1995-5869P	P 19951026
			GB 1996-2853	A 19960213
AU 9674637	A1	19970515	AU 1996-74637	19961022
			US 1995-5869P	P 19951026
			GB 1996-2853	A 19960213
			WO 1996-US16871W	19961022
US 5932559	A	19990803	US 1998-51948	19980423
			GB 1996-2853	A 19960213
			WO 1996-US16871W	19961022

OS MARPAT 127:17433

IT **190271-06-8P 190271-24-0P 190271-33-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of cyclopentyl derivs. as tachykinin receptor antagonists)

RN 190271-06-8 CAPLUS

CN Cyclohexanecarboxylic acid, 3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190271-24-0 CAPLUS

CN Cyclohexanecarboxylic acid, 3-[[[2-methoxy-5-(1H-tetrazol-1-yl)phenyl]methyl][(phenylmethoxy)carbonyl]amino]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190271-33-1 CAPLUS

CN Cyclohexanecarboxylic acid, 3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **190269-13-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of cyclopentyl derivs. as tachykinin receptor antagonists)

RN 190269-13-7 CAPLUS

CN Cyclohexanecarboxylic acid, 3-[[[2-methoxy-5-(1H-tetrazol-1-yl)phenyl]methyl]amino]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



I II

AB The invention is directed to certain novel compds. I and their pharmaceutically acceptable salts [wherein R3 = H, OH, alkoxy, Ph, cyano, halo, (un)substituted NH2, heterocyclyl, etc.; R6, R7, R8 = H, alkoxy, halo, (un)substituted alkyl, OH, cyano, CF3, etc.; R11, R12, R13 = H, (un)substituted alkyl, halo, cyano, CF3, etc.; A = benzene or various heterocycles; Q = H, alkyl; W = O, NH, alkylimino, NHCO, alkyliminocarbonyl; X = H, alkyl; Y = bond, (un)substituted alkyl; Z = (un)substituted NH, CONH, NHCO, SO2NH, NHSO2, SO2, CO2H, etc.; n = 1, 2, 3]. The invention is also concerned with pharmaceutical formulations comprising I as active ingredients, and use of I and their formulations in the treatment of certain disorders. I are tachykinin receptor antagonists (no data) and are useful in the treatment of inflammatory diseases, pain, migraine, asthma, and emesis. For instance, reductive alkylation of the appropriate amine with 2-methoxy-5-(1-tetrazolyl)benzaldehyde, by treatment with AcOH and 3A sieves in MeOH followed by NaBH3CN, gave title compound II.

L5 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1989:457465 CAPLUS
DN 111:57465
TI Highly selective κ-opioid analgesics. 2. Synthesis and structure activity relationships of novel N-(2-aminocyclohexyl)arylacetamide derivatives
AU Halfpenny, Paul R.; Hill, Raymond G.; Horwell, David C.; Hughes, John; Hunter, John C.; Johnson, Stephen; Rees, David C.
CS Parke-Davis Res. Unit, Addenbrookes Hosp., Cambridge, CB2 2QB, UK
SO Journal of Medicinal Chemistry (1989), 32(7), 1620-6
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 111:57465
IT **121212-14-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with benzofuranmethanamine)
RN 121212-14-4 CAPLUS
CN Cyclohexanecarboxylic acid, 2-(1-pyrrolidinyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



I

AB The structure-activity relationships of the title compds. were investigated by consideration of structural modifications made to the aromatic moiety, the amide and the other ring substituents of the κ-selective agonist trans-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl)benzo[b]**thiophene**-4-acetamide (I). The κ and μ opioid receptor binding affinities of 23 novel compds. are reported. Optimal μ/κ receptor selectivity is obtained with a benzo[b]**thiophene** system attached via the C-4 position, which is discussed in terms of steric and electronic parameters. The amide linkage was replaced with the reversed amide, an ester, an aminomethylene, a thioamide, and a secondary amide. The best of these isosteres is the N-methylamide. Substitution of the pyrrolidine ring in the 3-position with a CH2OH group increases the μ/κ selectivity. trans-(±)-N-Methyl-N-[4,5-dimethoxy-2-(1-pyrrolidinyl)cyclohexyl)benzo[b]**thiophene**-4-acetamide has high in vitro κ opioid receptor affinity (k1 = 16 nM) and equipotent analgesic activity to morphine i.v. in rats.

L5 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1988:5676 CAPLUS
DN 108:5676
TI Syntheses of cyclopentene annulated and heterocyclic PAHs (polycyclic aromatic hydrocarbons)
AU Lee-Ruff, Edward; Kruk, Henry; Chung, Ying Shen; Halliday, Jennifer; Kazarians-Moghaddam, Hira; Maleki, Mehran; Katz, Morris
CS Dep. Chem., York Univ., Toronto, ON, M3J 1P3, Can.
SO Polynucl. Aromat. Hydrocarbons: Chem., Charact. Carcinog., Int. Symp., 9th (1986), Meeting Date 1984, 489-94. Editor(s): Cooke, Marcus; Dennis, Anthony J. Publisher: Battelle Press, Columbus, Ohio.
CODEN: 55SUAC
DT Conference
LA English
IT **107010-14-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and Friedel-Crafts cyclization of, with hydrogen fluoride)
RN 107010-14-0 CAPLUS
CN Cyclohexanecarboxylic acid, 2-(2,3-dihydro-1H-inden-1-yl)- (9CI) (CA INDEX NAME)



AB Cyclopentene annulated and heterocyclic PAHs were prepared by two general routes. Cycloaddn. of aryl ketenes with cyclohexadiene, dihydrofuran, and dihydrothiophene gave spirocyclobutanone derivs. These strained intermediates underwent selective acid or base ring opening reactions, which upon further structural elaboration, gave PAHs with cyclopentene, furan, or **thiophene** rings. Electrocyclization of diaryl(carbomethoxy) carbocations gave fluorene derived PAHs.

L5 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1976:164551 CAPLUS
DN 84:164551
TI Synthesis of the three isomeric ortho-substituted phenylthienyl benzoic acids
AU Johnson, Alexander L.
CS Exp. Stn., E. I. du Pont de Nemours and Co., Wilmington, DE, USA
SO Journal of Organic Chemistry (1976), 41(8), 1320-4
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English
OS CASREACT 84:164551
IT **58268-02-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 58268-02-3 CAPLUS
CN Cyclohexanecarboxylic acid, 2-(4-phenyl-2-thienyl)-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



I, R=$C_6H_4CO_2H$-2
III, R=CH:$CHCO_2Me$
IV, R=CHO

AB 2-(3-Phenyl-2-thienyl)benzoic acid (I; Ph in 3-position) (II) was prepared via the Ullmann reaction of 2-iodo-3-phenylthiophene with 2-IC6H4CO2Me. The two isomers of II were prepared by Diels-Alder reaction of the resp. acrylates III (prepared by Knoevenagel reaction of the aldehydes IV with malonic acid) with butadiene, followed by dehydrogenation of the resulting carbomethoxycyclohexene derivs. with 2,3-dichloro-4,5-dicyanobenzoquinone and Saponification

L5 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1968:486735 CAPLUS
DN 69:86735
TI Acetylcholine. XII. 3,4-Diphenylthiophene-2.5-dicarboxylic acid bis [(β-diethylamino)ethyl ester methiodide], a curarelike muscle-relaxant ester
AU Dann, O.; Bamberg, K. J.; Sucker, H.
CS Univ. Erlangen-Nuernberg, Erlangen-Nuernberg, Fed. Rep. Ger.
SO Pharmazie (1968), 23(3), 135-45
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA German
IT **19950-50-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 19950-50-6 CAPLUS
CN 1,2-Cyclohexanedicarboxylic acid, 3,6-diphenyl-, all-cis- (8CI) (CA INDEX NAME)

Relative stereochemistry.



GI For diagram(s), see printed CA Issue.
AB The muscle-relaxing properties of quaternized amino alc. esters of 3,4-diphenyl- (I), 3,4-dimethyl- (II), 3,4-di(2-furyl)- (III), and 3,4-bis(5-nitro-2-furyl)**thiophene**-2,5-dicarboxylic acid (IV); phenanthreno[9,10-c]**thiophene**-1,3-dicarboxylic acid (V); and 2,3-diphenylbenzene-1,4- (VI), 3,6-diphenylbenzene-1,2- (VII), and 2,5-diphenylfuran-3,4-dicarboxylic acid (VIII) were determined I (10 g.) was boiled with 300 ml. SOCl2 and worked up to give 8.1 g. I dichloride (IX), m. 123-4°. Similarly prepared were 37% II dichloride (X), m. 67-73°; III dichloride (XI), 91%, m. 90.5-1.5° (ligroine); IV dichloride, m. 92.5-95° (C6H6); V dichloride (XII), 37%, m. 193-4° (C6H6); and VI dichloride (XIII), 80%, m. 153.5-56° (decomposition) (ligroine). VIII (5.5 g.) was added in small portions with stirring to an ice-cold suspension of 16 g. PCl5 in 55 ml. Et2O, stirred 30 min., and worked up to give 4.8 g. VIII dichloride (XIV), m. 120-1° (twice from ligroine). Crude II in dioxane was treated with CH2N2 in Et2O, kept 3 hrs., and worked up to give 36% di-Me ester, m. 171.5-2.5° (also prepared by heating X and MeOH), which was refluxed in methanolic KOH and worked up to give pure II, decompose 324-7°. Similarly, III (at -5°), gave 90% di-Me ester, m. 129° (twice from AcOH), which, at -5° in Ac2O, was nitrated with HNO3 (d. 1.52), stirred 1 hr., and worked up to give IV di-Me ester, m. 182-4°, which refluxed 2 min. in methanolic KOH and worked up gave IV, m. 258° (decomposition). A suspension of 2 g. 1,4-dimethyl-2,3-diphenylbenzene in 60 ml. C5H5N and 20 ml. H2O containing 25.3 g. KMnO4 was

refluxed 2 hrs. and worked up to give 2.2 g. VI, m. 308-11°. IX (15.6 g.) and 25.2 g. β-diethylaminoethanol (DEAE) was refluxed 6 hrs. in 500 ml. dry C6H6 and worked up to give 14.8 g. I bis(β-diethylaminoethyl ester), m. 76.5-77° (ligroine); dipicrate m. 175.5-77° (1:1 Me2CO-H2O); di-HBr salt m. 185.5-6.5° (Me2CO-iso-PrOH); dimethiodide m. 212-13° (decomposition); bis(benzyl bromide) decomposed 191°, m. 240-7° (EtOH-EtOAc). The following were prepared II bis(β-diethylaminoethyl ester), 70% [di-HBr salt m. 212.5-14° (decomposition); dimethiodide m. 202.5-2.5° (decomposition)]; III bis(β-diethylaminoethyl ester), 61%, n22D 1.459, by shaking XI and DEAE in C6H6 66 hrs. at room temperature and working up [di-HBr salt, m. 179.5-81° (decomposition); dimethiodide m. 177.5-79° (decomposition)]; IV bis(β-diethylaminoethyl ester), 47%, m. 42-7° (dimethiodide m. 192-5°); VI bis(β-diethylaminoethyl ester), 62%, n22D 1.540 [di-HBr salt m. 185.5-7.5° (EtOAc:EtOH); dimethiodide, m. 234-5° (decomposition)]; VIII bis(β-diethylaminoethyl ester), 74% [di-HBr salt m. 180-1° (3:1 Me2CO-EtOH); dimethiodide m. 185.5-87° (decomposition)] I bis(β-dimethylaminoethyl ester) 65%, m. 69-79° (ligroine) [dimethiodide decomposed 225-50° (EtOH)]; and V bis(β-diethylaminoethyl ester), 90%, [di-HCl salt, decompose 211-12.5°; dimethiodide m. 215-16° (decomposition)]. XII (1.25 g.) and 1.1 g. MeOH refluxed in 5 ml. C6H6 and cooled precipitated 0.85 g. V di-Me ester, m. 118-19°. DEAE (4.7 g.) in 50 ml. Me2CO was added to 12 g. VII anhydride suspended in 250 ml. dry refluxing Me2CO, and the mixture refluxed 20 min. to precipitate 14.6 g. of the half ester, m. 205-22°, difficulty soluble in 2N NaOH and 2N HCl. This intermediate (8.35 g.) and 5.4 g. β-diethylaminoethyl chloride was refluxed 6.5 hrs. in 160 ml. dry iso-PrOH and worked up to give 7.3 g. VII bis(β-diethylaminoethyl ester), m. 99-100° (ligroine and petroleum ether); di-HBr salt m. 193-5°; dimethiodide m. 206.5-7.5° (decomposition). The anhydride (5 g.) of cis, cis, cis,cis-3,6-diphenyl-1,2,3,6-tetrahydrobenzene-1,2-dicarboxylic acid in 80 ml. HCONMe2 was hydrogenated at atmospheric pressure and room temperature over Pd(OH)2 on BaSO4 and worked up to give 3.3 g. anhydride of cis, cis, cis, cis-3,6-diphenylcyclohexane-1,2-dicarboxylic acid, m. 220-2° (EtOAc). A solution of 4.8 g. 2,7-diaminodiphenylene sulfone and 14 g. di-Et diacetylsuccinate in 20 ml. AcOH was refluxed 45 min. and cooled to precipitate 12.5 g. XV, m. 251-3° (BuOH:AcOH), saponified to the free acid by methanolic KOH. A mixture of 1.28 g. 2,2'-dihydroxy-5,5'-dimethyldeoxybenzoin in 2N NaOH and 1 g. ClCH2CO2H solution neutralized with K2CO3 was refluxed 3 hrs. and worked up to give 2-hydroxy-2'-carboxymethoxy-5,5'-dimethyldeoxybenzoin, m. 159-61° (60% EtOH), and 2,2'-dicarboxymethoxy-5,5'-dimethyldeoxybenzoin, m. 172-4° (60% AcOH and 60% EtOH). Extensive biol. data are given.

L5 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1946:11414 CAPLUS
DN 40:11414
OREF 40:2139c-i,2140a-c
TI Synthesis of trans-anti-trans-9-ketoperhydrophenanthrene
AU Bhattacharyya, Bidyut Kamal
CS Univ. Coll. of Sci. and Technol., Calcutta, India
SO J. Indian Chem. Soc. (1945), 22, 85-90
DT Journal
LA Unavailable

IT **6715-08-8**, Diphenic acid, dodecahydro-
(preparation of)
RN 6715-08-8 CAPLUS
CN [1,1'-Bicyclohexyl]-2,2'-dicarboxylic acid (9CI) (CA INDEX NAME)



AB A method is described for the synthesis of the perhydrophenanthrene ring that has the same stereochem. configuration as the cholane system occurring in nature. A cold solution of 210 g. of cyclohexanone cyanohydrin in 272 g. of C5H5N with 130 cc. of SOCl2 gave 167 g. of 1-cyanocyclohexene (I), 13.6 g. of which upon refluxing for 36 hrs. with 25 cc. of "rectified spirit" and 4.3 cc. of concentrated H2SO4 gave 13 g. of Et 1-cyclohexene-1-carboxylate (II). II was also obtained by the stepwise hydrolysis and esterification of I. A mixture of 181 g. of II, 168 cc. of NCCH2CO2Et, 370 cc. of EtOH, and EtONa (from 30.2 g. of Na) heated on the water bath for 30 hrs., diluted with iced dilute HCl, extracted with Et2O, washed with NaHCO3 solution, dried, and distilled gave 228 g. of Et 2-carbethoxy-α-cyanocyclohexaneacetate (III). Et δ-iodovalerate (56 g.) added to the K derivative of III (from 70 g. of III, 9 g. of K, and 150 cc. of xylene), left overnight, heated on the water bath for 12 hrs., heated at 110° for 12 hrs., refluxed in an oil bath for 12 hrs., washed 3 times with H2O, dried, and distilled gave 56 g. of di-Et α-cyano-α-(2-carbethoxycyclohexyl)pimelate (IV), b0.4 179-82°. IV was obtained similarly also from Et δ-bromovalerate, 50 g. of which had been obtained from 150 cc. of EtOH, 9 cc. of H2SO4, and 50 g. of Br(CH2)4CO2H. Refluxing of 56 g. of IV with 140 cc. of AcOH, 100 cc. of H2SO4, and 140 cc. of H2O for 36 hrs. gave upon dilution the crude acid, which after extraction with Et2O was refluxed for 40 hrs. with 200 cc. of EtOH and 28 cc. of H2SO4 to give 42 g. of di-Et α-(2-carbethoxycyclohexyl)pimelate (V), b4 190°. V (33 g.) in 160 cc. of C6H6 was refluxed with 4 g. of Na dust until all the Na reacted, treated with iced dilute H2SO4, extracted with Et2O, washed with NaHCO3, dried, the Et2O and C6H6 distilled off, the residue mixed with the oil obtained by acidification of the NaHCO3 washing, refluxed for 30 hrs. with 20 cc. of AcOH, 100 cc. of concentrated HCl, and 10 cc. of H2O, the acid and H2O removed under reduced pressure, and the residue refluxed for 24 hrs. with 100 cc. EtOH and 10 cc. of H2SO4 to give 2-(2-carbethoxycyclohexyl)cyclohexanone (VI), b4.5 151°. Refluxing VI with an excess of NH2OH.HCl, C5H5N, and EtOH gave the oxime, m. 138-40°. Unsuccessful attempts were made to prepare VI from EtOK and II, from Et potassiocyclohexanone-2-carboxylate and II, and from sodiocyclohexanone and II. VI (17 g.) was refluxed for 2 hrs. with a mixture of 150 cc. of **thiophene**-free C6H6, 5 g. of Zn, 8 cc. of BrCH2CO2Et (VII), and a crystal of iodine; 2 g. of Zn, another crystal of iodine, and 4 cc. of VII were added and the refluxing continued for 1 hr.; 2 g. of Zn and a crystal of iodine were added and the refluxing continued for 2 hrs.; the product was decomposed with iced dilute H2SO4, extracted with C6H6, washed with dilute NH3 and H2O to give Et 2-(2-carbethoxycyclohexyl)-1-hydroxycyclohexaneacetate, b0.4 140-150°, which when left overnight with 100 cc. of Et2O, 20 cc. of

C5H5N, and 10 cc. of SOCl2 and decomposed with iced dilute acid gave 5.8 g. of Et 2-(2-carbethoxycyclohexyl)-1-cyclohexene-1-acetate (VIII), b4 180°. VIII (5 g.) was refluxed for 2 hrs. with 5 g. of KOH in 50 cc. of MeOH and then for 7 hrs. with 5 g. of KOH in 5 cc. of H2O. The MeOH was removed and the residue extracted with Et2O, acidified with AcOH, and extracted with Et2O again. Evaporation of the 2nd extract gave a residue that when crystallized from AcOH with C and then from MeOH gave 3 g. of 2-(2-carboxycyclohexyl-1-cyclohexene-1-acetic acid, m. 195-205° (decomposition), 2.8 g. of which upon hydrogenation in AcOH over 0.3 g. of Adams catalyst gave 2-(2-carboxycyclohexyl) cyclohexaneacetic acid (IX), crystallized from C6H6, m. 188-9°. IX (2.8 g.) in 200 cc. of Et2O was treated with CH2N2 in Et2O, allowed to stand for 2 days, the excess CH2N2 destroyed with AcOH, and the Et2O layer washed with NaHSO3 solution, dried, and distilled to give 2.8 g. of Me 2-(2-carbomethoxycyclohexyl)cyclohexaneacetate, b3 153°, which when refluxed for 6 hrs. with 0.46 g. of Na dust and 40 cc. of benzene, worked up as before, hydrolyzed as before, and distilled gave 1.2 g. of 9-ketoperhydrophenanthrene (X), b4.5 133°. Refluxing 0.4 g. of X for 4 hrs. with 0.6 g. NH2OH.HCl, 1 cc. of C5H5N, and 2.5 cc. of EtOH, dilution, and crystallization of the precipitate from EtOH gave the oxime, m. 226-7°, which upon refluxing for 6 hrs. with 5% H2SO4 regenerated X, m. 46-7.5°. Heating 0.7 g. of X with 3.2 cc. of a 1:3 mixture of concentrated and fuming HNO3 for 45 min. on a steam bath, dilution, and crystallization from dilute AcOH gave perhydrodiphenic acid.

```
=> d his

     (FILE 'HOME' ENTERED AT 13:03:54 ON 28 APR 2004)

     FILE 'REGISTRY' ENTERED AT 13:04:22 ON 28 APR 2004
L1              STRUCTURE UPLOADED
L2          434 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:04:56 ON 28 APR 2004
L3          307 S L2
L4           94 S L3 AND PHENYL
L5           11 S L3 AND THIOPHENE
L6            5 S L3 AND DISEASES

=> d l3 and cardiovascular
'AND' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
'CARDIOVASCULAR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
```

```
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d his

     (FILE 'HOME' ENTERED AT 13:03:54 ON 28 APR 2004)

     FILE 'REGISTRY' ENTERED AT 13:04:22 ON 28 APR 2004
L1             STRUCTURE UPLOADED
L2          434 S L1 SSS FULL
```

FILE 'CAPLUS' ENTERED AT 13:04:56 ON 28 APR 2004
L3 307 S L2
L4 94 S L3 AND PHENYL
L5 11 S L3 AND THIOPHENE
L6 5 S L3 AND DISEASES

=> s l3 and cardiovascular
L7 11 L3 AND CARDIOVASCULAR

=> d l7 fbib hitstr abs total

L7 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:814621 CAPLUS
DN 140:281158
TI Design, Pharmacokinetic, and Pharmacodynamic Evaluation of a New Class of Soft Anticholinergics
AU Huang, Fenglei; Browne, Clinton E.; Wu, Whei-Mei; Juhasz, Attila; Ji, Fubao; Bodor, Nicholas
CS College of Pharmacy, Center for Drug Discovery, University of Florida, Gainesville, FL, 32610, USA
SO Pharmaceutical Research (2003), 20(10), 1681-1689
CODEN: PHREEB; ISSN: 0724-8741
PB Kluwer Academic/Plenum Publishers
DT Journal
LA English
IT **21472-50-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics)
RN 21472-50-4 CAPLUS
CN Cyclohexanecarboxylic acid, 2-hydroxy-2-phenyl- (8CI, 9CI) (CA INDEX NAME)



AB Purpose. To design and evaluate a new class of soft anticholinergics with subtype selectivity. Methods. A new class of soft anticholinergics was designed based on the "inactive metabolite" approach. Four compds. were synthesized. The potency and soft nature of the compds. were evaluated by receptor binding, cardiac, and mydriatic studies. Stability and pharmacokinetic studies were also performed on these newly synthesized soft anticholinergics. Results. Receptor binding studies of the soft anticholinergics on cloned muscarinic receptors indicated pKi values in the range of 7.5 to 8.9. Two compds., 9a and 13a, of the series showed muscarinic subtype receptor selectivity (M3/M2). In mydriatic studies, 13a and 13b showed shorter duration of action in the treated eyes than tropicamide. In the control eyes, significant dilation of pupils was found only in rabbits treated with atropine and tropicamide, indicating that the soft anticholinergics lack systemic effects because of their facile hydrolytic deactivation. Consistent with their soft nature, this

AB Title compds., e.g. (I), were prepared for use in treating **cardiovascular** ischemic disorders in humans or animals. Thus, 2-(2-hydroxyethoxymethyl)pyrido[2,3-d]imidazole (preparation given) was reacted with (1R,2R)-2-(4-methylphenyl)cyclohexanecarboxylic acid (resolution from racemate given) to yield the intermediate material which was reacted with (S)-phenylglycinamide hydrochloride to give I. In in vitro tests of rabbit erythrocyte adenosine uptake, the 2-(morpholin-4-yl)methyl [in place of the 2-(2-hydroxyethoxymethyl) sidechain] compound had IC50 of 15 nM; the 2-(piperazinyl)benzimidazolyl variant had IC50 of 25 nM.

L7 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:567333 CAPLUS
DN 125:221843
TI Preparation of benzylimidazole derivatives for the treatment of vascular restenosis
IN Mueller-Gliemann, Matthias; Mueller, Ulrich; Beuck, Martin; Zaiss, Siegfried; Gerdes, Christoph; Domdey-Bette, Anke; Gruetzmann, Rudi; Lohmer, Stefan; Wohlfeil, Stefan; et al.
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 725064	A1	19960807	EP 1996-100760	19960119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				DE 1995-19503160A	19950201
	DE 19503160	A1	19960808	DE 1995-19503160	19950201
	TW 448176	B	20010801	TW 1996-85100684	19960122
				DE 1995-19503160A	19950201
	RO 117256	B1	20011228	RO 1996-152	19960126
				DE 1995-19503160A	19950201
	CA 2168317	AA	19960802	CA 1996-2168317	19960129
				DE 1995-19503160A	19950201
	JP 08253453	A2	19961001	JP 1996-33174	19960129
				DE 1995-19503160A	19950201
	IL 116931	A1	20000601	IL 1996-116931	19960129
				DE 1995-19503160A	19950201
	FI 9600425	A	19960802	FI 1996-425	19960130
				DE 1995-19503160A	19950201
	AU 9642240	A1	19960808	AU 1996-42240	19960130
	AU 710235	B2	19990916		
				DE 1995-19503160A	19950201
	BG 63044	B1	20010228	BG 1996-100326	19960130
				DE 1995-19503160A	19950201
	BG 103820	A	20010928	BG 1999-103820	19960130
				DE 1995-19503160A	19950201
	NO 9600414	A	19960802	NO 1996-414	19960131
				DE 1995-19503160A	19950201
	ZA 9600725	A	19960820	ZA 1996-725	19960131
				DE 1995-19503160A	19950201
	RU 2158261	C2	20001027	RU 1996-101800	19960131
				DE 1995-19503160A	19950201
	CN 1137380	A	19961211	CN 1996-102574	19960201

US 5935983	A	19990810	DE 1995-19503160A US 1997-960075 DE 1995-19503160A US 1996-588477 B1	19950201 19971024 19950201 19960118

OS MARPAT 125:221843

IT **181130-44-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzylimidazole derivs. for the treatment of vascular restenosis)

RN 181130-44-9 CAPLUS

CN Cyclohexanecarboxylic acid, 2-[4-[[2-(1-methylethyl)-1H-benzimidazol-1-yl]methyl]phenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



I

AB The title compds. [I; D = CH, N; R1 = Ph, cycloalkyl, (un)branched alkyl; R2 = (un)branched alkoxycarbonyl, CH2OH, CONH2], useful for the treatment of vascular restenosis, are prepared Thus, I (D = N, R1 = CHMe2, R2 = CONH2; * * cyclohexyl ring bonding is trans) was prepared and demonstrated a IC50 of 0.01 nM for the inhibition of rat aorta smooth muscle proliferation.

L7 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:560541 CAPLUS
DN 125:221572
TI Preparation of substituted 3-benzylindole antiatherosclerotics
IN Mueller-Gliemann, Matthias; Mueller, Ulrich; Beuck, Martin; Zaiss, Sigfried; Gerdes, Christoph; Domdey-Better, Anke; Gruetzmann, Rudi; Lohmer, Stefan; Wohlfeil, Stefan; et al.
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 725061	A1	19960807	EP 1996-100761	19960119
	EP 725061	B1	20000607		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	DE 19513716	A1	19960808	DE 1995-19513716	19950411
				DE 1995-19503159A1	19950201
	HR 960015	B1	20001231	HR 1996-960015	19960115
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	AT 193701	E	20000615	AT 1996-100761	19960119
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	ES 2148600	T3	20001016	ES 1996-100761	19960119
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	PT 725061	T	20001130	PT 1996-96100761	19960119
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	JP 08253451	A2	19961001	JP 1996-30123	19960125
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	CA 2168320	AA	19960802	CA 1996-2168320	19960129
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	FI 9600424	A	19960802	FI 1996-424	19960130
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	AU 9642241	A1	19960808	AU 1996-42241	19960130
	AU 708784	B2	19990812		
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	IL 116956	A1	20000217	IL 1996-116956	19960130
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411

NO 9600413	A	19960802	NO 1996-413 19960131 DE 1995-19503159A 19950201 DE 1995-19513716A 19950411
ZA 9600726	A	19960820	ZA 1996-726 19960131 DE 1995-19503159A 19950201
RU 2162842	C2	20010210	RU 1996-101801 19960131 DE 1995-19503159A 19950201
CN 1137520	A	19961211	CN 1996-102575 19960201
CN 1067987	B	20010704	DE 1995-19503159A 19950201 DE 1995-19513716A 19950411
GR 3034245	T3	20001229	GR 2000-401932 20000823 DE 1995-19503159A 19950201 DE 1995-19513716A 19950411

OS MARPAT 125:221572

IT **181070-77-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted 3-benzylindole antiatherosclerotics)

RN 181070-77-9 CAPLUS

CN Cyclohexanecarboxylic acid, 2-[4-[(2-phenyl-1H-indol-3-yl)methyl]phenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



I



II

AB The title compds. [I; R1 = Ph, cycloalkyl, (un)branched alkyl; R2 = H, (un)branched alkyl; R3 = CONH2, CH2OH], useful for the treatment of atherosclerosis or restenosis, are prepared Thus, II, prepared from phenylglycinamide, demonstrated a IC50 of 0.052 nM against the proliferation of pig aorta smooth muscle.

L7 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:523976 CAPLUS
DN 125:168010
TI Preparation of 2,9-disubstituted purin-6-ones as antiinflammatories and **cardiovascular** agents.
IN Niewoehner, Ulrich; Bischoff, Erwin; Schuetz, Helmuth; Perzborn, Elisabeth; Schramm, Matthias
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 722944	A1	19960724	EP 1996-100156	19960108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				DE 1995-19501482	19950119
	DE 19501482	A1	19960725	DE 1995-19501482	19950119
	US 5861404	A	19990119	US 1996-587321	19960112
				DE 1995-19501482	19950119
	AU 9640979	A1	19960725	AU 1996-40979	19960115
				DE 1995-19501482	19950119
	CA 2167353	AA	19960720	CA 1996-2167353	19960116
				DE 1995-19501482	19950119
	IL 116769	A1	19981206	IL 1996-116769	19960116
				DE 1995-19501482	19950119
	FI 9600225	A	19960720	FI 1996-225	19960117
				DE 1995-19501482	19950119
	NO 9600223	A	19960722	NO 1996-223	19960118
				DE 1995-19501482	19950119
	ZA 9600398	A	19960828	ZA 1996-398	19960118
				DE 1995-19501482	19950119
	JP 08231545	A2	19960910	JP 1996-23473	19960118
				DE 1995-19501482	19950119
	BR 9600147	A	19980106	BR 1996-147	19960118
				DE 1995-19501482	19950119
	CN 1135485	A	19961113	CN 1996-101917	19960119
				DE 1995-19501482	19950119

OS MARPAT 125:168010
IT **180343-02-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,9-disubstituted purin-6-ones as antiinflammatories and **cardiovascular** agents)
RN 180343-02-6 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[6,9-dihydro-9-(1-methyl-4-phenylbutyl)-6-oxo-1H-purin-2-yl]- (9CI) (CA INDEX NAME)



GI



I

AB Title compds. [I; R1 = alkyl, (substituted) phenylalkyl; R2 = H, OH, N3, alkyl, OSO2R5; R5 = alkyl; R3 = H; R2R3 = O; R4 = H, alkyl; A = alkyl, 3,4-methylenedioxy, cycloalkyl, (substituted) Ph], were prepared Thus, I [A = cyclopropyl; R1 = Ph(CH2)3; R2, R3, R4 = H] (schematic preparation given) inhibited phosphodiesterases I, II, and V with IC50 = 4 μM, 0.6 μM, and 0.3 μM, resp.

L7 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:960198 CAPLUS
DN 124:8834
TI Preparation of (oxopyridazinyl)pyrazolopyridines as adenosine antagonists
IN Akahane, Atsushi; Nishimura, Shintaro; Itani, Hiromichi; Durkin, Kieran P. M.
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9518128	A1	19950706	WO 1994-JP2230	19941226
	W: AU, CA, CN, FI, HU, JP, KR, NO, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				GB 1993-26524 A	19931229
				GB 1994-4323 A	19940304
	CA 2180253	AA	19950706	CA 1994-2180253	19941226
				GB 1993-26524 A	19931229

				GB 1994-4323 A 19940304
AU 9512817	A1	19950717	AU 1995-12817	19941226
AU 694157	B2	19980716		
				GB 1993-26524 A 19931229
				GB 1994-4323 A 19940304
				WO 1994-JP2230 W 19941226
EP 737193	A1	19961016	EP 1995-903969	19941226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				GB 1993-26524 A 19931229
				GB 1994-4323 A 19940304
				WO 1994-JP2230 W 19941226
CN 1139928	A	19970108	CN 1994-194724	19941226
CN 1046724	B	19991124		
				GB 1993-26524 A 19931229
				GB 1994-4323 A 19940304
HU 76280	A2	19970728	HU 1996-1789	19941226
				GB 1993-26524 A 19931229
				GB 1994-4323 A 19940304
JP 09507485	T2	19970729	JP 1994-517911	19941226
				GB 1993-26524 A 19931229
				GB 1994-4323 A 19940304
				WO 1994-JP2230 W 19941226
ZA 9410409	A	19950926	ZA 1994-10409	19941229
				GB 1993-26524 A 19931229
IL 112193	A1	20001031	IL 1994-112193	19941229
				GB 1993-26524 A 19931229
				GB 1994-4323 A 19940304
BR 9500905	A	19951024	BR 1995-905	19950306
				GB 1994-4323 A 19940304
US 5773530	A	19980630	US 1996-663119	19960913
				GB 1993-26524 A 19931229
				GB 1994-4323 A 19940304
				WO 1994-JP2230 W 19941226
US 6355640	B1	20020312	US 1998-72696	19980506
				GB 1993-26524 A 19931229
				GB 1994-4323 A 19940304
				WO 1994-JP2230 A119941226
				US 1996-663119 A119960913

OS MARPAT 124:8834

IT **171050-83-2P 171051-51-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (oxopyridazinyl)pyrazolopyridines as adenosine antagonists)

RN 171050-83-2 CAPLUS

CN Cyclohexanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 171051-51-7 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[6-oxo-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-1(6H)-pyridazinyl]- (9CI) (CA INDEX NAME)



GI



I



II

AB Title compds. [I; R1 = aryl; R2 = (un)substituted cycloalkyl] were prepared Thus, I (R1 = Ph, R2 = H) was alkylated by 2-chlorocyclohexanone and the product condensed with (EtO)2P(O)CH2CO2Et to give, after saponification, title compound II and the exo-unsatd. product. II gave reduction of serum creatinine from 3.60 (control) to 1.10mg/dL i.v. in rats experiencing cisplatin-induced renal failure.

L7 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1994:245104 CAPLUS
DN 120:245104
TI Preparation of [(imidazolomethyl)phenyl]cyclohexanecarboxylates as angiotensin II antagonists
IN Mueller, Ulrich; Dressel, Juergen; Fey, Peter; Hanko, Rudolf; Huebsch, Walter; Kraemer, Thomas; Mueller-Gliemann, Matthias; Beuck, Martin; Kazda, Stanislav Prof Dr; et al.

PA Bayer A.-G., Germany
SO Ger. Offen., 20 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4221009	A1	19940105	DE 1992-4221009	19920626
	NO 9302133	A	19931227	NO 1993-2133	19930610
				DE 1992-4221009A	19920626
	EP 581003	A1	19940202	EP 1993-109465	19930614
	EP 581003	B1	20000906		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				DE 1992-4221009A	19920626
	AT 196136	E	20000915	AT 1993-109465	19930614
				DE 1992-4221009A	19920626
	ES 2151891	T3	20010116	ES 1993-109465	19930614
				DE 1992-4221009A	19920626
	CZ 282309	B6	19970611	CZ 1993-1173	19930616
				DE 1992-4221009A	19920626
	US 5508299	A	19960416	US 1993-80853	19930621
				DE 1992-4221009A	19920626
	CA 2099078	AA	19931227	CA 1993-2099078	19930623
				DE 1992-4221009A	19920626
	AU 9341463	A1	19940106	AU 1993-41463	19930623
	AU 666732	B2	19960222		
				DE 1992-4221009A	19920626
	IL 106107	A1	19970930	IL 1993-106107	19930623
				DE 1992-4221009A	19920626
	JP 06073016	A2	19940315	JP 1993-177438	19930624
				DE 1992-4221009A	19920626
	ZA 9304583	A	19940202	ZA 1993-4583	19930625
				DE 1992-4221009A	19920626
	HU 64753	A2	19940228	HU 1993-1870	19930625
				DE 1992-4221009A	19920626
	RU 2110514	C1	19980510	RU 1993-46254	19930625
				DE 1992-4221009A	19920626
	SK 281028	B6	20001107	SK 1993-668	19930625
				DE 1992-4221009A	19920626
	CN 1082538	A	19940223	CN 1993-107418	19930626
	CN 1037512	B	19980225		
				DE 1992-4221009A	19920626
	CN 1182734	A	19980527	CN 1997-109705	19970416
				DE 1992-4221009A	19920626

OS MARPAT 120:245104
IT **154063-56-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of angiotensin II antagonist)
RN 154063-56-6 CAPLUS
CN Cyclohexanecarboxylic acid, 2-(4-methylphenyl)-, (1R,2R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **154063-45-3P 154063-46-4P 154063-47-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II antagonist)
RN 154063-45-3 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]phenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 154063-46-4 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[4-[[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]phenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 154063-47-5 CAPLUS
CN 1H-Imidazole-5-carboxylic acid, 2-butyl-1-[[4-(2-carboxycyclohexyl)phenyl]methyl]-4-chloro-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



I

AB Title compds. [I; R = imidazolo group Q; A = (cyclo)alkyl, alkenyl; B = H, halo, perfluoroalkyl; D = CH2OR3, COR4; R1 = H, halo, OH, alkyl, etc.; R2 = COR5, CONR6R7, (triphenylmethyl)tetrazolyl; R3,R6 = H, alkyl; R4 = H, OH, alkoxy; R5 = OH, alkoxy; R7 = SO2R9, CHPhCH2OR10; R9 = (phenyl)alkyl, Ph, etc.; R10 = H, alkyl, hydroxy-protective group] were prepared Thus, 4-MeC6H4CH:CHCO2H was cyclocondensed with CH2:CHCH:CH2 and the product converted in 3 steps to trans-I (R1 = H, R2 = COR5)(II; R = Br, R5 = OCMe3) which was condensed with 2-butyl-4-chloro-5-formylimidazole and the product converted in 2 steps to II (R = Q, A = Bu, B = Cl, R5 = CONHSO2C6H4Me-4)(III; D = CHO). Similarly prepared III (D = CO2H) had IC50 of 240nM against angiotensin II-induced contraction of rabbit aortal rings in vitro.

L7 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:558581 CAPLUS
DN 115:158581
TI Preparation of cycloalkyl-substituted glutaramides as diuretic agents
IN Danilewicz, John Christopher
PA Pfizer Ltd., UK; Pfizer Inc.
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9107378	A1	19910530	WO 1990-EP1887	19901109
	W: CA, FI, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
				GB 1989-26063	19891117
	CA 2067197	AA	19910518	CA 1990-2067197	19901109
				GB 1989-26063	19891117
	EP 500621	A1	19920902	EP 1990-916253	19901109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				GB 1989-26063	19891117
				WO 1990-EP1887	19901109
	JP 04505625	T2	19921001	JP 1990-515157	19901109
	JP 06045583	B4	19940615		
				GB 1989-26063	19891117
				WO 1990-EP1887	19901109
	FI 9201949	A	19920430	FI 1992-1949	19920430
				GB 1989-26063	19891117
				WO 1990-EP1887	19901109

OS MARPAT 115:158581
IT **136145-51-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as diuretic agent)
RN 136145-51-2 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[1-(2-carboxy-4-methoxybutyl)cyclopentyl]carbonyl]amino]-2-phenyl- (9CI) (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.

AB The title compds. [I; A = (mono-un)saturated 4- to 7-membered carbocyclic ring optionally fused to a further (un)saturated 5- or 6-membered carbocyclic ring; m = 1-3; R, R4 = H, C1-6 alkyl, PhCH2, biolabile ester-forming group; R1 = H, C1-4 alkyl; R2 = C1-6 alkyl substituted by C1-4 alkoxy, aryl or aryloxy; R5 = (un)substituted C1-6 alkyl, C2-6 alkenyl or alkynyl, C3-7 cycloalkyl or cycloalkenyl], useful for the treatment of various **cardiovascular** disorders such as hypertension, heart failure, and renal insufficiency (no data), are prepared I are inhibitors of the Zn-dependent, neutral endopeptidase E.C. 3.4.24.11 which is involved in the breakdown of peptide hormones, e.g. atrial natriuretic factor. Thus, 2.4 mmol EtN:C:N(CH2)3NMe2.HCl was added to an ice-cold stirred solution of benzyl 3-(1-carboxycyclopentyl)-2-(2-methoxyethyl)propanoate, Et cis-4-amino-cis-2-(2-phenylethyl)cyclohexane-1-carboxylate, 1-hydroxybenzotriazole, and N-methylmorpholine in CH2Cl2 and the mixture was stirred for 0.5 h, warmed to room temperature, and stirred at room temperature for 20 h to give title compound (II). A total of 46 I were prepared

```
=> d his

     (FILE 'HOME' ENTERED AT 13:03:54 ON 28 APR 2004)

     FILE 'REGISTRY' ENTERED AT 13:04:22 ON 28 APR 2004
L1             STRUCTURE UPLOADED
L2          434 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:04:56 ON 28 APR 2004
L3          307 S L2
L4           94 S L3 AND PHENYL
L5           11 S L3 AND THIOPHENE
L6            5 S L3 AND DISEASES
L7           11 S L3 AND CARDIOVASCULAR

=> d l3 fbib hitstr abs total

L3   ANSWER 1 OF 307  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2004:217338  CAPLUS
DN   140:278505
TI   Asymmetric anhydrides, polyamic acids, polyimides, and polyamideimides
     therefrom, varnishes and liquid crystal alignment layers therefrom, and
     displays therewith
IN   Tamura, Norihisa
PA   Chisso Corp., Japan; Chisso Petrochemical Corporation
SO   Jpn. Kokai Tokkyo Koho, 82 pp.
```

AB Title compds., e.g. I, were prepared for use in treating ischemic brain diseases in humans or animals. Thus I [X = N, X1 = O (II)] was prepared in six steps, starting from 2,3-diaminopyridine, glycolic acid, (1R,2R)-2-(4-bromomethylphenyl)cyclohexane-1-carboxylic acid tert-Bu ester (preparation given), and (S)-phenylglycinamide hydrochloride. Similarly prepared was I [X = C, X1 = N(Me) (III)]. In in vivo (binding of calf cortex adenosine transport protein) compds. II and III had Ki = 2 nM. In in vitro tests of rat brain reperfusion injury, II and III were effective at 0.001 mg/kg, reducing infarct volume 81-91% of control.

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:234512 CAPLUS
DN 126:264005
TI Substituted indole derivatives useful as antiproliferatives, for treatment of arteriosclerosis and restenosis.
IN Mueller-Gliemann, Matthias; Mueller, Ulrich; Beuck, Martin; Zaiss, Siegfried; Gerdes, Christoph; Domdey-Bette, Anke; Gruetzmann, Rudi; Lohmer, Stefan; Wohlfeil, Stefan; Yalkinoglu, Ozkan; Elting, James; Denzer, Dirk
PA Bayer A-G, Germany
SO U.S., 7 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5607962	A	19970304	US 1996-591329	19960125
			DE 1995-19503150	19950201
			DE 1995-19513176	19950411

OS MARPAT 126:264005
IT **181070-80-4P 181070-82-6P 181228-88-6P 181228-90-0P 188778-95-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted indole derivs. for treatment of restenosis and arteriosclerosis)
RN 181070-80-4 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[(2-phenyl-1H-indol-3-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 181070-82-6 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[(1-methyl-2-phenyl-1H-indol-3-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]-, [1α(S*),2β]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 181228-88-6 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[(2-phenyl-1H-indol-3-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]-, [1α(R*),2β]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 181228-90-0 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[(1-methyl-2-phenyl-1H-indol-3-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]-, [1α(R*),2β]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 188778-95-2 CAPLUS
CN Benzeneacetamide, α-[[[2-[4-[(2-phenyl-1H-indol-3-yl)methyl]phenyl]cyclohexyl]carbonyl]amino]-, [1α(S*),2β]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



I



II

AB Substituted indole derivs. I [R1 = Ph, C3-6 cycloalkyl, C1-5 alkyl; R2 = H, C1-8 alkyl; R3 = CONH2, CH2OH] and salts are prepared by reacting appropriate carboxylic acids, possibly in the presence of auxiliaries, with appropriate amines. I are suitable as active ingredients of medicaments, particularly for the treatment of arteriosclerosis and restenosis. For instance, 2-phenylindole was alkylated in the 3-position by trans-tert-Bu 2-[p-(bromomethyl)phenyl]cyclohexane-1-carboxylate and KOBu-tert in DMF (19%), followed by acid hydrolysis of the tert-Bu ester using CF3CO2H in CH2Cl2 (100%), and amidation of the resulting acid with phenylglycinamide, to give 2 trans diastereomers of title compound II (51.6% major product isomer). In a cell culture assay for antiproliferative effect via inhibition of 3H-thymidine incorporation into porcine aortal DNA, one diastereomer of II had an IC50 of 0.02 nM.

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:567333 CAPLUS
DN 125:221843
TI Preparation of benzylimidazole derivatives for the treatment of vascular restenosis
IN Mueller-Gliemann, Matthias; Mueller, Ulrich; Beuck, Martin; Zaiss,

IT **100419-22-5P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and crystal structure of)
RN 100419-22-5 CAPLUS
CN Cyclohexanecarboxylic acid, 2-(1,3,4,5,6,7-hexahydro-3-oxo-1-isobenzofuranyl)-, [1α,2β(S*)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



I

AB The decarboxylation of some dicarboxylic anhydrides by catalytic influence of tertiary amines occurs at surprisingly low temperature (≥80°). The product I formed from two mols. of hexahydrophthalic anhydride with loss of one mol. of carbon dioxide, has been isolated and characterized by spectroscopic investigations and x-ray structure anal.

L3 ANSWER 117 OF 307 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1985:504607 CAPLUS
DN 103:104607
TI Cyclohexanecarboxylic acids and their derivatives as antidysrhythmic agents
IN Davidson, Thomas A.; Thomas, Telfer L.
PA Pennwalt Corp. , USA
SO Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 134889	A2	19850327	EP 1984-104894	19840502

EP 134889	A3	19850731			
EP 134889	B1	19871111			
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
			US 1983-524701	19830819	
AT 30715	E	19871115	AT 1984-104894	19840502	
			US 1983-524701	19830819	
			EP 1984-104894	19840502	
AU 8427695	A1	19850221	AU 1984-27695	19840504	
AU 563091	B2	19870625			
			US 1983-524701	19830819	
JP 60058951	A2	19850405	JP 1984-157720	19840730	
			US 1983-524701	19830819	
FI 8403241	A	19850220	FI 1984-3241	19840816	
			US 1983-524701	19830819	
DK 8403957	A	19850220	DK 1984-3957	19840817	
			US 1983-524701	19830819	
NO 8403307	A	19850220	NO 1984-3307	19840817	
			US 1983-524701	19830819	
US 4595759	A	19860617	US 1985-701797	19850215	
			US 1983-524701	19830819	

OS CASREACT 103:104607

IT **97906-58-6DP**, derivative
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antidysrhythmic activity of)

RN 97906-58-6 CAPLUS

CN Cyclohexanecarboxylic acid, 2-phenyl- (6CI, 9CI) (CA INDEX NAME)



IT **97857-50-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 97857-50-6 CAPLUS

CN Cyclohexanecarboxylic acid, 1-[3-(dimethylamino)propyl]-2-hydroxy-2-phenyl- (9CI) (CA INDEX NAME)



GI



I

AB The title compds. [I; D = CH, N; R1 = Ph, cycloalkyl, (un)branched alkyl; R2 = (un)branched alkoxycarbonyl, CH2OH, CONH2], useful for the treatment of vascular restenosis, are prepared Thus, I (D = N, R1 = CHMe2, R2 = CONH2; * * cyclohexyl ring bonding is trans) was prepared and demonstrated a IC50 of 0.01 nM for the inhibition of rat aorta smooth muscle proliferation.

L3 ANSWER 59 OF 307 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:560541 CAPLUS
DN 125:221572
TI Preparation of substituted 3-benzylindole antiatherosclerotics
IN Mueller-Gliemann, Matthias; Mueller, Ulrich; Beuck, Martin; Zaiss, Sigfried; Gerdes, Christoph; Domdey-Better, Anke; Gruetzmann, Rudi; Lohmer, Stefan; Wohlfeil, Stefan; et al.
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 725061	A1	19960807	EP 1996-100761	19960119
	EP 725061	B1	20000607		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	DE 19513716	A1	19960808	DE 1995-19513716	19950411
				DE 1995-19503159A1	19950201
	HR 960015	B1	20001231	HR 1996-960015	19960115
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	AT 193701	E	20000615	AT 1996-100761	19960119
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	ES 2148600	T3	20001016	ES 1996-100761	19960119
				DE 1995-19503159A	19950201
				DE 1995-19513716A	19950411
	PT 725061	T	20001130	PT 1996-96100761	19960119

			DE 1995-19503159A 19950201 DE 1995-19513716A 19950411
JP 08253451	A2	19961001	JP 1996-30123 19960125 DE 1995-19503159A 19950201 DE 1995-19513716A 19950411
CA 2168320	AA	19960802	CA 1996-2168320 19960129 DE 1995-19503159A 19950201 DE 1995-19513716A 19950411
FI 9600424	A	19960802	FI 1996-424 19960130 DE 1995-19503159A 19950201 DE 1995-19513716A 19950411
AU 9642241 AU 708784	A1 B2	19960808 19990812	AU 1996-42241 19960130 DE 1995-19503159A 19950201 DE 1995-19513716A 19950411
IL 116956	A1	20000217	IL 1996-116956 19960130 DE 1995-19503159A 19950201 DE 1995-19513716A 19950411
NO 9600413	A	19960802	NO 1996-413 19960131 DE 1995-19503159A 19950201 DE 1995-19513716A 19950411
ZA 9600726	A	19960820	ZA 1996-726 19960131 DE 1995-19503159A 19950201
RU 2162842	C2	20010210	RU 1996-101801 19960131 DE 1995-19503159A 19950201
CN 1137520 CN 1067987	A B	19961211 20010704	CN 1996-102575 19960201 DE 1995-19503159A 19950201 DE 1995-19513716A 19950411
GR 3034245	T3	20001229	GR 2000-401932 20000823 DE 1995-19503159A 19950201 DE 1995-19513716A 19950411

OS MARPAT 125:221572

IT **181070-77-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted 3-benzylindole antiatherosclerotics)

RN 181070-77-9 CAPLUS

CN Cyclohexanecarboxylic acid, 2-[4-[(2-phenyl-1H-indol-3-yl)methyl]phenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



GI



I



II

AB The title compds. [I; R1 = Ph, cycloalkyl, (un)branched alkyl; R2 = H, (un)branched alkyl; R3 = CONH2, CH2OH], useful for the treatment of atherosclerosis or restenosis, are prepared Thus, II, prepared from phenylglycinamide, demonstrated a IC50 of 0.052 nM against the proliferation of pig aorta smooth muscle.

L3 ANSWER 60 OF 307 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:523976 CAPLUS
DN 125:168010
TI Preparation of 2,9-disubstituted purin-6-ones as antiinflammatories and cardiovascular agents.
IN Niewoehner, Ulrich; Bischoff, Erwin; Schuetz, Helmuth; Perzborn, Elisabeth; Schramm, Matthias
PA Bayer A.-G., Germany
SO Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 722944	A1	19960724	EP 1996-100156	19960108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
			DE 1995-19501482	19950119
DE 19501482	A1	19960725	DE 1995-19501482	19950119
US 5861404	A	19990119	US 1996-587321	19960112
			DE 1995-19501482	19950119
AU 9640979	A1	19960725	AU 1996-40979	19960115
			DE 1995-19501482	19950119
CA 2167353	AA	19960720	CA 1996-2167353	19960116
			DE 1995-19501482	19950119
IL 116769	A1	19981206	IL 1996-116769	19960116
			DE 1995-19501482	19950119
FI 9600225	A	19960720	FI 1996-225	19960117
			DE 1995-19501482	19950119
NO 9600223	A	19960722	NO 1996-223	19960118
			DE 1995-19501482	19950119
ZA 9600398	A	19960828	ZA 1996-398	19960118

				DE 1995-19501482 19950119
	JP 08231545	A2	19960910	JP 1996-23473 19960118
				DE 1995-19501482 19950119
	BR 9600147	A	19980106	BR 1996-147 19960118
				DE 1995-19501482 19950119
	CN 1135485	A	19961113	CN 1996-101917 19960119
				DE 1995-19501482 19950119

OS MARPAT 125:168010

IT **180343-02-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,9-disubstituted purin-6-ones as antiinflammatories and cardiovascular agents)

RN 180343-02-6 CAPLUS

CN Cyclohexanecarboxylic acid, 2-[6,9-dihydro-9-(1-methyl-4-phenylbutyl)-6-oxo-1H-purin-2-yl]- (9CI) (CA INDEX NAME)



GI



I

AB Title compds. [I; R1 = alkyl, (substituted) phenylalkyl; R2 = H, OH, N3, alkyl, OSO2R5; R5 = alkyl; R3 = H; R2R3 = O; R4 = H, alkyl; A = alkyl, 3,4-methylenedioxy, cycloalkyl, (substituted) Ph], were prepared Thus, I [A = cyclopropyl; R1 = Ph(CH2)3; R2, R3, R4 = H] (schematic preparation given) inhibited phosphodiesterases I, II, and V with IC50 = 4 μM, 0.6 μM, and 0.3 μM, resp.

L3 ANSWER 61 OF 307 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:298558 CAPLUS

DN 125:86495

GI



I

AB A stereoselective approach to densely functionalized cyclohexanoids from 7-norbornenone is detailed. Construction of the phenanthridone core I present in pancratistatin was accomplished via this protocol.

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 48 OF 307 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:306975 CAPLUS
DN 129:15967
TI Preparation of arylcycloalkanes as tachykinin receptor antagonists.
IN Caldwell, Charles G.; Chen, Ping; Durette, Philippe L.; Finke, Paul; Hale, Jeffrey; Holson, Edward; Kopka, Ihor; Maccoss, Malcolm; Meurer, Laura; Mills, Sander G.; Robichaud, Albert
PA Merck and Co., Inc., USA
SO U.S., 109 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5750549	A	19980512	US 1996-730277	19961015
				US 1996-730277	19961015

OS MARPAT 129:15967
IT **190269-13-7P 190271-06-8P 190271-24-0P**
190271-33-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylcycloalkanes as tachykinin receptor antagonists)
RN 190269-13-7 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[[[2-methoxy-5-(1H-tetrazol-1-yl)phenyl]methyl]amino]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190271-06-8 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190271-24-0 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[[[2-methoxy-5-(1H-tetrazol-1-yl)phenyl]methyl][(phenylmethoxy)carbonyl]amino]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 190271-33-1 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-phenyl-, (1S,2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



GI



AB Title compds. [I; R3 = H, alkoxy, phenylalkoxy, Ph, cyano, halo, amino, (substituted) alkyl, null; R6-R8 = H, alkoxy, halo, (substituted) alkyl, OH, cyano, CF3, NO2, heterocyclyl, etc.; R11-R13 = H, (substituted) alkyl, halo, cyano, CF3, NO2, OH, alkoxy, etc.; A = Ph, benzofuranyl, benzothiophenyl, benzothiazoyl, indolyl, imidazolyl, oxadiazolyl, pyridyl, pyrimidyl, quinolinyl, thiazolyl, thienyl, thiophenyl, dihydrobenzofuranyl; Q = H, alkyl; W = O, NH, alkylimino, NHCO, alkyliminocarbonyl; X = H, alkyl; Y = bond, (substituted) alkyl; Z = NR15, CONR15, SO2NR15, SO2, CO2R15, CH2OR15, null; R15 = H, (substituted) alkyl; n = 1-3; with provisos], were prepared Thus, Me 3(SR)-hydroxy-2(RS)-phenylcyclopentane-1(RS)-carboxylate (preparation given) was treated with 3,5-bis(trifluoromethyl)benzyl bromide and NaH in DMF to give Me 3(SR)-[3,5-bis(trifluoromethyl)phenylmethoxy]-2(RS)-phenylcyclopentane-1(RS)-carboxylate. I showed intrinsic tachykinin receptor antagonist activity in the range 0.05-10 μM.

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 49 OF 307 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:80846 CAPLUS
DN 128:180454
TI Phosphine-directed stereo- & regioselective Ni-catalyzed reactions of Grignard reagents with allylic ethers
AU Didiuk, Mary T.; Morken, James P.; Hoveyda, Amir H.
CS Dep. Chem., Merkert Chem. Cent., Boston Coll., Chestnut Hill, MA, 02167, USA
SO Tetrahedron (1998), 54(7), 1117-1130
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier Science Ltd.
DT Journal
LA English
IT **203316-96-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT



I



II



III

AB The title composition contains a compound generating acid upon active ray or radiation irradiation and a resin having ≥1 monovalent polycyclic alicyclic group of I, II, or III [R1-5 = alkyl, cycloalkyl, alkenyl, alkynyl (these groups may be substituted), halo, CN, R6OR7, R8CO2R9, R10CONR11R12, R13OCOR14; R7, R9 = H, alkyl, cycloalkyl, alkenyl (these groups may be substituted), group that is decomposed by the action of acid to increase the solubility in alkaline developing solns.; R11, R12, R14 = H, alkyl, cycloalkyl, alkenyl (these groups may be substituted), R11 and R12 may link to form a ring; R6, R8, R10, R13 = single bond, alkylene, alkenylene, cycloalkylene (these groups may be substituted); l, m, n, p, q = 0-5, when l, m, n, p, q ≥ 2, the plural groups in each R1-5 may be different, when 2 groups in each R1-5 are substituted at the same C atom, they may represent carbonyl or thiocarbonyl group, when 2 groups in each R1-5 are substituted at adjacent C atoms, they may link to form double bond between these C atoms, when ≥2 groups in each R1-5 are substituted, they may link to form a ring; I, II, and III may link to the resin at any position in the polycyclic structures] and a group that is decomposed by the action of acid to increase the solubility in alkaline developing solns. The composition shows high sensitivity to UV ray of ≤250 nm, especially ≤220 nm and provides high resolution patterns with good profile and dry etch resistance. The composition gives fine patterns and is useful of manufacture of semiconductor devices.

L3 ANSWER 43 OF 307 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:545694 CAPLUS
DN 129:223253
TI Positive-working photoresist composition
IN Aogo, Toshiaki; Sato, Kenichiro
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 58 pp.
CODEN: JKXXAF
DT Patent

LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10221852	A2	19980821	JP 1997-24011	19970206
				JP 1997-24011	19970206

IT **212580-07-9P**
RL: PNU (Preparation, unclassified); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(photoresist composition containing polymer having acid-generating group, alicyclic group, and alkali-soluble group)

RN 212580-07-9 CAPLUS

CN 2-Butenedioic acid, methyl 1-(1-methylethoxy)ethyl ester, polymer with 2-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)cyclohexanecarboxylic acid, 9,10-dimethoxy-2-anthracenyl 4-ethenylphenyl disulfone and 1-tricyclo[3.3.1.13,7]dec-1-ylethyl 2-methyl-2-propenoate (9CI) (CA INDEX NAME)

CM 1

CRN 212580-06-8
CMF C11 H13 N O4



CM 2

CRN 212580-05-7
CMF C10 H16 O5



CM 3

CRN 212580-04-6
CMF C16 H24 O2



CM 4

CRN 212580-03-5
CMF C24 H20 O6 S2



AB The title composition comprises a resin having ≥1 repeating unit containing groups that are decomposed upon active ray or irradiation to generate acid, ≥1 alicyclic group-containing repeating unit, and ≥1 repeating unit containing groups that are decomposed by the action of acid to increase the solubility in alkaline developing solns. The composition shows high sensitivity toward light of wavelength ≤250 nm, especially ≤220 nm, and high dry etch resistance and provides high resolution resist patterns with good profile independent of the elapse of time from exposure to post-bake.

L3 ANSWER 44 OF 307 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:485041 CAPLUS
DN 129:122567
TI Preparation of ethanobenzoisoindole derivatives as farnesyl transferase inhibitors
IN Bourzat, Jean-Dominique; Commercon, Alain; Dereu, Norbert; Mailliet, Patrick; Sounigo-Thompson, Fabienne; Martin, Jean-Paul; Capet, Marc; Cheve, Michel
PA Rhone-Poulenc Rorer S.A., Fr.
SO PCT Int. Appl., 260 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9829390	A1	19980709	WO 1997-FR2407	19971223

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG,